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ABSTRACT 
 
Once pathogens have entered an organism, the host immune system has to recognise 
and respond immediately to the microorganisms and their immunogenic products. 
Following recognition by pattern recognition receptors, the production and auto-/paracrine 
action of signalling molecules (e.g. cytokines) the Janus kinase and signal transducer and 
activator of transcription (Jak-Stat) signalling pathway becomes activated. In response to 
outside signals this pathway can alter nuclear gene expression programs within minutes, 
thereby modulating cellular processes like development, cell growth and homeostasis. As 
a result, deregulation of the Jak-Stat signalling pathway can lead to severe consequences 
for an organism. Tyrosine kinase 2 (Tyk2) is one of four mammalian Jaks that participate 
in the Jak-Stat signalling pathway and engagement of Tyk2 in response to a variety of 
cytokines and some growth factors has been demonstrated. Accordingly, Tyk2-deficient 
mice are more susceptible to most microbial infections, which is mainly attributed to their 
defects in type I interferon (IFN#/!) and interleukin (IL)-12 signalling. In contrast, Tyk2-
deficient mice are resistant to lipopolysaccharide (LPS)- and intestinal ischemia/ 
reperfusion-induced shock. Additionally, Tyk2 has also been linked to the development of 
autoimmune and inflammatory diseases. 
In order to study how Tyk2 globally influences the response to LPS we have recently 
conducted transcriptome and proteome studies in macrophages. Aim of this study was to 
confirm and further characterise the kinetics and mechanism(s) of induction of selected 
Tyk2-regulated genes/proteins. Furthermore, to substantiate our findings in vivo, we 
examined gene induction, organ and cell type specificity of the most interesting 
gene(s)/protein(s).  
Two genes that we analysed in more detail are IL-17 and IL-17F. Both are important 
proinflammatory cytokines involved in the pathogenesis of several autoimmune and 
inflammatory diseases and are nonetheless essential for the host defence against many 
microbes. We could show that Tyk2 positively regulates expression of IL-17 and IL-17F in 
macrophages at the transcriptional level and demonstrate that this function of Tyk2 does 
not depend on IFN#/! signalling. Our study revealed that Tyk2 is also involved in IL-17 
production in spleens following intraperitoneal administration of LPS. Additionally, we can 
show that IL-17 in spleens is almost exclusively produced by two cell types, i.e. "& T cells 
and plasmacytoid dendritic cells (pDCs). Interestingly, it has not been reported until yet 
that pDCs are capable of IL-17 production. 
A third gene that we focussed on was IL-1!. The substantial contribution of IL-1! to a 
variety of autoimmune and inflammatory diseases is well known, but Tyk2 has not yet 
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been linked to the control of IL-1! expression. Regulation of IL-1! at the transcriptional 
level and by proteolytic processing from pro-IL1! to the mature form has already been 
described. Our study in macrophages revealed that Tyk2 suppresses IL-1! expression in 
response to LPS at the translational level, thereby uncovering a novel mechanism of IL-1! 
regulation. By showing increased IL-1! production in the absence of IFN#/! receptor 1 
(Ifnar1) and Stat1, we provide evidence for the involvement of canonical IFN#/! signalling. 
We could demonstrate a similar Tyk2-dependent downregulation of IL-1! following Listeria 
monocytogenes infection in macrophages. In support of our in vitro data, IL-1! levels were 
increased in the peritoneal lavages of Tyk2-deficient mice after LPS challenge, 
highlighting the importance of Tyk2-mediated translational regulation of IL-1!. In contrast 
to local IL-1! expression, systemic IL-1! levels were decreased in the absence of Tyk2, 
further illustrating the complexity of IL-1! regulation. 
In summary, this study provides novel insights in the diverse and non-redundant 
regulatory functions of Tyk2 in vitro and in vivo. Tyk2 can modulate processes as diverse 
as transcription and translation. In particular, we identified IL-17 as LPS-induced and 
Tyk2-dependent gene in inflammatory macrophage populations in vitro and in "& T cells 
and pDCs in spleens. In addition, we identified a Tyk2-dependent inhibitory loop that limits 
excessive IL-1! production in response to LPS treatment and Listeria monocytogenes 
infection. We show that this suppressive effect occurs at the translational level, thereby 
identifying a novel mode of IL-1! regulation. 
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ZUSAMMENFASSUNG 
 
Sind Pathogene erst einmal in einen Organismus eingedrungen, ist es die Aufgabe des 
Immunsystems diese zu erkennen und umgehend auf die Mikroorganismen und ihre 
immunogenen Produkte zu reagieren. Nach dem Erkennen durch Muster-Erkennungs-
Rezeptoren, der Produktion und auto-/paracrinen Wirkung von Signalmolekülen (wie z.B. 
Zytokinen) wird die Jak-Stat (Janus Kinase - Signal Transducer and Activator of 
Transcription) Signaltransduktionskaskade aktiviert. Als Antwort auf äußere Signale kann 
diese Kaskade die Genexpression im Kern innerhalb von Minuten modifizieren und 
dadurch zelluläre Prozesse wie Entwicklung, Zellwachstum und Homeostase an äußere 
Gegebenheiten anpassen. Dementsprechend kann die Deregulierung der Jak-Stat Signal-
transduktionskaskade mit erheblichen Konsequenzen für einen Organismus verbunden 
sein. Tyrosin Kinase 2 (Tyk2) ist eine der vier Säugetier-Jaks, von denen alle an der Jak-
Stat Signaltransduktionskaskade beteiligt sein können. Es konnte gezeigt werden, dass 
Tyk2 an der Reaktion auf eine Vielzahl von Zytokinen und einigen Wachstumsfaktoren 
mitwirkt. Folglich sind Tyk2-defiziente Mäuse anfälliger gegenüber den meisten 
mikrobiellen Infektionen, was hauptsächlich auf die Defekte in der Typ I Interferon 
(IFN#/!) und Interleukin (IL)-12 Signaltransduktion zurückzuführen ist. Im Gegensatz 
dazu sind Tyk2-defiziente Mäuse resistent gegen Schock induziert durch Lipopoly-
saccharid (LPS) und intestinale Ischämie/Reperfusion. Zusätzlich wurde Tyk2 mit der 
Entstehung von Autoimmun- und entzündlichen Krankheiten in Zusammenhang gebracht. 
Um herauszufinden, wie Tyk2 global die Antwort auf LPS beeinflusst, führten wir 
Transkriptom- und Proteom-Studien durch. Ziel dieser Arbeit war, die Kinetik und die 
Mechanismen der Induktion ausgewählter, Tyk2-regulierter Gene/Proteine zu bestätigen 
und im Detail zu charakterisieren. Außerdem untersuchten wir Geninduktion, Organ- und 
Zelltypspezifität der interessantesten Gene/Proteine in vivo, um unsere Ergebnisse zu 
bekräftigen. 
Zwei Gene, die wir genauer analysierten sind IL-17 und IL-17F, bedeutende,  
entzündungsfördernde Zytokine, welche in die Pathogenese verschiedener Autoimmun- 
und entzündlicher Krankheiten involviert, jedoch essentiell für die Abwehr von Mikroben 
sind. Wir konnten zeigen, dass Tyk2 die Expression von IL-17 und IL17F auf 
transkriptioneller Ebene in Makrophagen positiv reguliert, und dass diese Tyk2-Funktion 
nicht von der IFN#/! Signaltransduktion abhängt. Unsere Studie ergab weiters, dass Tyk2 
auch die IL-17 Produktion in der Milz, nach intraperitonealer Administration von LPS, 
beeinflusst. Zusätzlich konnten wir zeigen, dass IL-17 in der Milz fast ausschließlich von 
zwei Zelltypen, nämlich "& T Zellen und plasmazytoiden dendritischen Zellen (pDCs), 
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produziert wird. Interessanterweise war bis jetzt noch nicht bekannt, dass pDCs IL-17 
produzieren können. 
Das dritte Gen, auf welches wir uns fokussierten, war IL-1!. Es ist bekannt, dass IL-1! 
substantiell an einer Vielzahl von Autoimmun- und entzündlichen Krankheiten beteiligt ist, 
allerdings wurde Tyk2 bis jetzt noch nicht mit der Kontrolle der IL-1! Expression in 
Zusammenhang gebracht. Die Regulation von IL-1! auf transkriptioneller Ebene und 
durch proteolytische Prozessierung von pro-IL-1! zur reifen Form wurde bereits 
beschrieben. Unsere Studie in Makrophagen zeigte, dass Tyk2 die Expression von IL-1! 
auf translationeller Ebene hemmt, womit wir eine neuartige Form der IL-1! Regulation 
aufdeckten. Dadurch, dass wir in Abwesenheit von IFN#/! Rezeptor 1 (Ifnar1) und Stat1 
erhöhte IL-1! Produktion zeigten, lieferten wir den Beweis für die Mitwirkung von 
kanonischer IFN#/! Signaltransduktion. Wir konnten eine gleichartige Tyk2-abhängige 
Reduktion von IL-1! nach Listeria monocytogenes Infektion in Makrophagen 
demonstrieren. Übereinstimmend mit unseren in vitro Daten, war die IL-1! Konzentration 
in peritonealen Spülungen Tyk2-defizienter Mäuse nach LPS erhöht, was die Wichtigkeit 
Tyk2-vermittelter translationeller Regulation von IL-1! weiter hervorhebt. Im Gegensatz zu 
lokaler IL-1! Expression war die Konzentration an systemischem IL-1! in der 
Abwesenheit von Tyk2 reduziert – ein weiterer Hinweis auf die komplexe Regulation von 
IL-1!. 
Zusammenfassend bietet diese Studie neuartige Einblicke in die vielschichtigen und 
spezifischen regulatorischen Funktionen von Tyk2 in vitro und in vivo. Tyk2 kann 
Prozesse so unterschiedlich wie Transkription und Translation modulieren. Insbesondere 
identifizierten wir IL-17 als LPS-induziertes Tyk2-abhängiges Gen in entzündlichen 
Makrophagen-Populationen in vitro und in "& T Zellen und pDCs in der Milz. Zusätzlich 
beschrieben wir einen Tyk2-abhängigen inhibitorischen Wirkungskreis, der übermäßige 
IL-1! Produktion nach LPS Behandlung oder Listeria monocytogenes Infektion limitiert. 
Wir zeigen, dass dieser hemmende Effekt auf translationeller Ebene stattfindet und stellen 
eine neuartige Form der IL-1! Regulation vor. 
! 13
INTRODUCTION 
 
1. The Immune System 
1.1. Overview 
Vertebrates are permanently colonised by and communicate with a variety of 
microorganisms. Interactions culminate in effects that may be either beneficial or 
pathogenic for the host. Microbial sensing mechanisms are needed to maintain host-
microbial homeostasis and to induce antimicrobial defense mechanisms, where 
necessary. In order to combat pathogenic microorganisms two types of immunity have 
evolved in mammals: the innate and the adaptive immune system. The evolutionary older 
innate immune system can be regarded as the first line of defense against infectious 
invaders. Highly conserved and invariant features of microbes are recognised by a limited 
number of germline-encoded receptors to discriminate self from non-self. Important cells 
involved in innate immune responses are phagocytes (i.e. neutrophiles, dendritic cells and 
macrophages), natural killer (NK) cells and "& T cells. This is in contrast to the more 
specific adaptive immunity, which is mediated mainly by T and B lymphocytes. Specificity 
is achieved by random somatic rearrangement of gene segments and clonal expansion 
leading to a huge repertoire of antigen-specific receptors. Compared to the innate, the 
adaptive immune responses develop later and it can take days to weeks until responses 
are mounted entirely. One important feature of adaptive immunity is the development of 
an immunological memory, thereby providing a mechanism to respond more vigorously to 
repeated exposures to the same pathogens. Both branches of the immune system are 
interrelated, act coordinated and in concert to immune stimuli as the innate immune 
system stimulates and influences the character of adaptive immune responses and as 
effector functions of innate immune cells are utilised by the adaptive immunity. Finally, 
termination of responses and return to a basal state (homeostasis) is an important 
function of the immune system [1, 2]. 
 
1.2. Pattern Recognition Receptors (PRRs) 
PRRs are microbial sensors utilised by the innate immune system, which are expressed 
almost ubiquitously and independent of immunological memory. PRRs recognise highly 
conserved structures that are often shared by all microorganisms of a given class, 
referred to as pathogen-associated molecular patterns (PAMPs), although they are not 
necessarily unique to pathogenic species. PAMPs are rather essential for microbial 
physiology and therefore difficult to alter. Endogenous danger or stress signals (so called 
danger-associated molecular patterns or DAMPs) are also detected by these receptors. 
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PRRs are located throughout the body either in body fluids, on cell membranes, in 
endosomal compartments or in the cytoplasm. They are essentially involved in 
mechanisms as diverse as opsonisation and phagocytosis, complement activation, 
presentation and transfer of PAMPs to other PRRs, and induction of major signalling 
pathways leading to the production of mainly proinflammatory cytokines, such as tumour 
necrosis factor # (TNF#) and interleukin(IL)-1!, but also type I interferons (IFNs). Different 
PRRs react with specific PAMPs and show distinct expression patterns. Important 
bacterial and fungal PAMPs like lipopolysaccharide (LPS) and !-glucan, respectively, are 
often components of the cell wall. In contrast, the main targets of sensing viruses are their 
nucleic acids. Discrimination between self (host) and non-self is based on the structure 
and specific chemical modifications that are unique to viral RNA and DNA, as well as on 
the cellular compartment in which the nucleic acids are located [2-5]. 
 
1.2.1. Toll-like Receptors (TLRs) 
The best characterised family of PRRs are the TLRs. Up until now, 11 human and 13 
mouse TLR members have been described. TLRs are expressed on various immune 
cells, including macrophages, dendritic cells (DCs), B cells, specific types of T cells, and 
even on certain types of non-immune cells. These type I integral membrane glycoproteins 
are characterised by an outside ligand binding domain consisting of leucine rich repeats 
(LRR) and an inside signalling Toll-/IL-1 receptor (TIR) domain. Following ligand binding 
the TIR domain interacts with one or more of the five TIR domain-containing adaptor 
molecules: MyD88, Mal, TRIF, TRAM and SARM. This leads to activation of various 
downstream signalling cascades and production of mainly proinflammatory cytokines and 
chemokines. PAMPs sensed by the TLR family range from lipids and lipopeptides, to 
proteins and nucleic acids. Based on their subcellular localisation TLRs can be further 
divided into two groups. The first group (TLR1, 2, 4, 5 and 6) is localised on the cell 
surface, therefore capable of sensing microbial cell wall components, and recognises lipid 
structures as well as flagellin. The endosome/lysosome membrane-located second group 
(TLR3, 7, 8 and 9) is specialised in the recognition of nucleic acids derived from viral or 
bacterial genomes. Nowadays it has become increasingly evident that TLR localisation 
and trafficking is an important regulatory mechanism and also prevents overactivation of 
TLR signalling pathways [3, 4, 6-8].  
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1.2.2. Cytoplasmic PRRs 
More recently, intracellular microbial sensors have been identified. They can be roughly 
subdivided into the nucleotide binding oligomerisation domain (NOD)-leucine rich repeat 
(LRR) proteins and the caspase recruitment domain (CARD)-helicase proteins, which are 
implicated in the recognition of bacterial and viral components, respectively. 
 
1.2.2.1. NOD-like Receptors (NLRs) 
NLRs function in complementing and synergising with TLRs in innate immunity. Their 
tripartite structure is composed of a variable N-terminal domain essential for protein-
protein interactions, a centrally located NOD domain facilitating self-oligomerisation after 
activation and a LRR domain at the C-terminus responsible for binding and detecting 
PAMPs. After oligomerisation so-called NOD signalosomes are assembled leading to the 
transcription of proinflammatory cytokines and chemokines following activation of nuclear 
factor-%B (NF-%B) and mitogen-activated protein kinase (MAPK) pathways. Some NLRs 
also sense DAMPs and form together with caspase-1 large cytoplasmic complexes, the 
inflammasomes, that are responsible for the proteolytic activation of the proinflammatory 
cytokines IL-1! and IL-18 [9, 10]. 
 
1.2.2.2. RIG-like Helicases (RLHs) 
To date, two RNA helicases, namely retinoic-acid-inducible gene 1 protein (RIG-I) and 
melanoma differentiation associated gene 5 (MDA5) are described to sense viral RNAs. 
Viral stimulation leads to the activation of NF-%B and IRF3/7 via the CARD adaptor protein 
Cardif (also known as IPS-1, MAVS or VISA), which in turn induces the transcription of 
proinflammatory cytokines and type I IFNs, respectively. LGP2, a third RLH that lacks the 
CARD domain, can act either as negative or positive regulator in the antiviral response, 
depending on the stimulus [9, 11]. 
 
1.2.3. Other PRRs 
A collectin family member, few complement components and several pentraxin family 
members constitute a group of PRRs residing in body fluids. They all play key roles in 
PAMP opsonisation and activation of the complement pathway [4]. A number of 
membrane bound PRRs, such as mannose receptor, scavenger receptors and the C-type 
lectin, and dectin-1, also promote phagocytosis. Dectin-1 additionally generates 
intracellular signals by itself and in conjunction with TLR2 and is the major sensor for 
antifungal immunity [4]. Recently, novel cytosolic DNA sensors have been uncovered 
including DNA-dependent activator of interferon regulatory factors (DAI, also known as 
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ZBP1 or DLM-1) and a HIN200 protein inflammasome containing AIM2 (absent in 
melanoma 2). At least in the murine system AIM2 is negatively regulated by p202, another 
HIN200 protein. These proteins sense dsDNA irrespective of the sequence but dependent 
on its length. However, additional evidence for the biological significance of DAI and the 
AIM2 inflammasome remains to be provided [4, 12]. Most recently, IFI16 and its mouse 
ortholog p204 have been added to the growing list of intracellular DNA sensors [13]. RNA 
polymerase III was identified as a cytosolic sensor for B-form dsDNA by two independent 
studies. Once recognised by cytosolic RNA polymerase III, B-form dsDNA is converted 
into a substrate for the RIG-I pathway that then induces type I IFN production [14, 15]. 
The cytosolic sensor LRRFIP1 has been reported to bind B- and Z-form dsDNA and to 
mediate type I IFN induction together with its downstream partner !-catenin via IRF3 [16]. 
The two DExD/H-box helicases DHX36 and DHX9 have been identified as specific 
sensors for CpG-A and CpG-B, respectively, in human pDCs. Both are critical for sensing 
viral DNA in the cytosol and trigger differential cytokine responses via MyD88-dependent 
activation of IFN regulatory factor 7 (IRF7) and NF-%B [17]. 
 
1.3. Lipopolysaccharide (LPS) 
Bacterial LPS (or endotoxin), a component of the outer cell wall of gram-negative bacteria, 
is a potent stimulator of the immune system. The polysaccharide groups of LPS, which 
might vary considerably in length and composition amongst bacterial species, are 
recognised by the adaptive immune system. In contrast, innate immune responses are 
induced by a conserved lipid moiety of LPS (lipid A) that is responsible for most of the 
toxic and pyrogenic properties of endotoxin. Local and systemic inflammation along with 
many other features of infection by gram-negative bacteria can be mimicked by 
administration of LPS alone, although the variation in biological activities of LPS 
originating from different bacteria has to be taken into account. High levels and prolonged 
production of various cytokines, reactive oxygen and nitrogen intermediates as well as 
other inflammatory mediators can lead to a condition designated septic (or endotoxin) 
shock, which is accompanied by tissue injury and multiorgan failure and often ends 
lethally for the host. Macrophages are of primary importance in this context as they 
produce all these components in response to LPS [1, 3, 18].  
 
1.3.1. LPS-induced TLR4 signalling pathways in macrophages 
The nature of the LPS signalling pathway was originally identified by two spontaneous 
mutations, rendering C3H/HeJ and C57BL/10ScCr mice unresponsive to LPS, as both 
mutations were located in the TLR4 gene. LPS liberated from gram-negative bacteria 
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associates with LPS binding protein (LBP), which in turn binds to membrane-bound CD14. 
LPS is then transferred to MD-2, which associates with the extracellular domain of TLR4, 
culminating in homodimerisation of the receptor complex and initiating signal transduction 
by the recruitment of intracellular adaptor molecules via their TIR domains. At least two 
distinct pathways are activated by LPS, the MyD88-dependent and the MyD88-
independent pathway. They modulate transcription, mRNA stability and/or translation of a 
number of proinflammatory cytokine genes such as TNF#, IL-12, IL-6, IL-1! and type I 
IFNs [3, 4, 18]. 
In MyD88-dependent signalling TIRAP/Mal serves as bridging adaptor between MyD88 
and TLR4. MyD88 then recruits and activates IRAK-4, followed by IRAK-2, IRAK-1 and 
IRAK-M. IRAK activation leads to association with TRAF6. After polyubiquitination of 
TRAF6 itself, IRAK-1 and NEMO, a complex composed of TGF-!-activated kinase 1 
(TAK1) and the TAK1 binding proteins (TAB1-3), is recruited to TRAF6. TAK1 then 
activates I%B kinase (IKK) and mitogen-activated protein kinases (MAPKs) such as p38, c-
jun N-terminal kinase (JNK) and extracellular signal-regulated kinases (ERKs). This 
ultimately leads to nuclear translocation and early activation of the transcription factors 
NF-%B and activator protein-1 (AP-1). MyD88 also directly interacts with IRF5 and upon 
translocation into the nucleus, a set of proinflammatory cytokine genes are induced by 
IRF5. Generally spoken, the MyD88-dependent pathway is crucial for driving 
proinflammatory responses [3, 19, 20].  
The MyD88-independent pathway is initiated by the adaptor TRIF. This adaptor is also 
linked to TRL4 by a membrane bound bridging adaptor, namely TRAM. Following 
internalisation and translocation to endosomes/lysosomes this receptor-complex 
associates with TRAF3. Most importantly, downstream of TRAF3, TBK1 and IKKi (IKK') 
are activated, which in turn phosphorylate IRF3. Then IRF3 homo- or heterodimers, 
containing the p65 subunit of NF-%B, translocate to the nucleus where they activate 
transcription of a subset of genes, including IFN!. TRAF6 is also activated by TRIF and 
that ultimately leads to the late activation of NF-%B, characterised by a second wave of 
proinflammatory cytokine expression [19, 21, 22]. In addition, TLRs 3, 4, 7, 8, 9 and in 
inflammatory monocytes also TLR2, induce type I IFN production through the activation of 
the transcription factors IRF3 and/or IRF7 [23]. In myeloid DCs IRF1 is activated by TLRs 
7, 8, 9 to induce IFN! production [8]. 
 
1.3.2. LPS in vivo 
LPS directly stimulates macrophages to secrete a number of cytokines and other 
inflammatory mediators, like type I IFNs and IL-12. Type I IFN signalling results in the 
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expression of numerous IFN-stimulated genes (ISGs), which comprise transcriptional and 
translational regulators and pro-apoptotic genes. IL-12 induces the local expression of 
IFN" by T cells and NK cells. IFN" then activates macrophages for phagocytosis and also 
augments the synthesis of proinflammatory cytokines. The actions of IL-12 are further 
complemented by IL-18. Type I IFNs together with IL-18 also can induce IFN" production. 
IL-10 acts as a negative feedback regulator, since it inhibits for instance IL-12 expression, 
and expression of co-stimulatory and class II MHC molecules, which are all produced by 
activated macrophages and DCs. Macrophage-derived cytokines, especially TNF#, IL-1! 
and IL-12 are responsible for the systemic manifestation of LPS challenge. Mild 
responses consist of neutrophilia, fever and a rise of acute-phase reactants in the plasma, 
mostly originating from the liver and upregulated by cytokines such as IL-6, IL-1! and 
TNF#. Upon presence of LPS in the blood (sepsis), circulating cytokine levels increase 
and the host response changes. Overproduction of cytokines and other harmful mediators 
(like nitric oxide) then can result in septic shock [1, 24]. The central role of type I IFNs in 
this context was demonstrated by the fact that IFN!-deficient mice are highly resistant to 
LPS induced endotoxin shock [25]. 
 
 
2. Jak-Stat signalling pathway 
 
2.1. Overview 
One of the best characterised pathways by which cytokines transduce their signals from 
the cell surface to the nucleus is the Janus kinase and signal transducer and activator of 
transcription (Jak-Stat) signalling pathway. This pathway was discovered by studies of IFN 
signalling and is used by all type I and II cytokine receptors. The sequential events 
leading to the transcriptional regulation of responsive genes are depicted in figure 1 (as 
exemplified for type I IFNs). Upon ligand binding, oligomerisation and subsequent 
activation of the respective receptor chains is initiated. Thereby Jaks bound to their 
cytoplasmic portion come into close proximity, auto- and/or cross-phosphorylate and 
phosphorylate tyrosine residues on the receptor chains. These are then recognised by the 
Src homology 2 (SH2) domains of specific Stats leading to their tyrosine phosphorylation 
and activation. Activated Stat homo- and/or heterodimers translocate to the nucleus 
where they bind to the promoter regions of target genes. Although only four Jaks and 
seven Stats exist, highly specific and diverse responses can be mounted by the different 
usage of various combinations of one or more Jaks and Stats. In addition other signalling 
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cascades and transcription factors can be activated, thereby adding another level of 
complexity to the biological responses to a given cytokine or growth factor [26-28]. 
 
 
 
Figure 1: The Jak-Stat signalling pathway. Schematic overview as exemplified for type I IFNs (see text for 
details). 
 
 
2.2. Janus Kinases (Jaks) 
There are four Jak family members (Jak1-3 and Tyk2) in mammals that range in size from 
120 to 140 kDa and, with the exception of Jak3, are expressed in most tissues. This 
family of non-receptor tyrosine kinases features seven conserved Jak homology (JH) 
domains. Notably, they possess a tandem set of C-terminal kinase domains, but only JH1 
is catalytically active, whereas JH2, referred to as pseudokinase domain, serves an 
essential regulatory role. Activation is driven by phosphorylation of critical tyrosines in the 
“inactivation loop”, thereby releasing the blockade of the catalytical site. So far no function 
has been assigned to the SH2-related domain (JH3 and half of JH4) but the N-terminal 
Four-point-one/Ezrin/Radixin/Moesin (FERM) domain (half of JH4 and JH5-7) is important 
for stable association with cognate receptor chains. 
Jak1 knock-out mice die perinatally due to defective leukemia inhibitory factor (LIF) 
receptor signalling. The critical role of this kinase in the response to IFNs, IL-10, IL-2/IL-4 
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and IL-6 cytokine families was clarified by analyses of cells and tissues from Jak1 
deficient mice. Consistent with a critical role in erythropoiesis, Jak2 knock-out mice die of 
anaemia prenatally (E12.5). Ex vivo studies on embryonal Jak2-/- cells and tissues 
revealed an important role in directing responses to IFN" and cytokines utilising the 
single-chain and IL-3 receptor families. Intriguingly, several myeloproliferative disorders 
observed in humans can be attributed to a single pointmutation in the JH2 domain of 
Jak2. Jak3 expression is mainly restricted to leukocytes, where this kinase exclusively 
associates with the IL-2 receptor "-chain ("c), a receptor component for a number of 
lymphotrophic cytokines. Mutations in either Jak3 or "c are associated with severe 
combined immunodeficiency (SCID) in humans and similarly, Jak3 knock-out mice 
develop an immunodeficiency syndrome, although less severe. Therefore, Jak3 has 
become an important therapeutic target [26-28]. 
 
2.3. Tyk2 
2.3.1. Tyk2 in cytokine signalling 
The essential role of Jak kinases in cytokine signalling was originally revealed for Tyk2 in 
type I IFN responses. Tyk2 associates with receptors for type I and type III IFNs (also 
designated IFN$s), IL-12/23, IL-6 and IL-10 cytokine families and mediates signals in 
combination with Jak1 and Jak2 but not Jak3 (figure 2). The two receptor chains of the 
type I IFN receptor, Ifnar1 and Ifnar2, are permanently associated with Tyk2 and Jak1, 
respectively. Tyk2-deficient human cell lines are unresponsive to IFN# and display partial 
defects in IFN! signalling [29]. Moreover steady-state expression of Ifnar1 is 
compromised in the absence of Tyk2 in these cells [30, 31]. Whereas type I IFN receptor 
signalling seems highly dependent on Tyk2 in humans, surprisingly modest effects were 
observed in the murine system and lack of responsiveness could be detected only with 
low concentrations of IFN#/! [32-34]. Although Tyk2 does not bind to the IFN" receptor 
(neither Ifngr1 nor Ifngr2 chain), IFN" signalling as well as production are both dependent 
on Tyk2, presumably due to reduced Stat1 protein levels and through impaired action of 
IL-12, respectively. Tyk2 is associated with the IL-12 receptor !1 (IL-12R!1) chain of the 
IL-12R and activates mainly Stat4, which is required for the activation of the IFN" gene. 
Interestingly, the Tyk2-associated IL-12R!1 chain is also part of the IL-23R complex, but 
different DNA-binding Stat complexes are formed in response to IL-23 as compared to IL-
12 [35, 36]. IL-23 is critically involved in the development of a growing number of 
autoimmune and inflammatory diseases, but the precise role of Tyk2 for IL-23-mediated 
responses remains to be determined [37]. Together with Jak1 and Jak2, Tyk2 is also 
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activated by cytokines that share the gp130 receptor chain, such as IL-6, IL-27, LIF and 
oncostatin M (OSM). As far as analysed, Tyk2 exerts rather ancillary or redundant 
functions in this context [32, 34, 38]. Some controversy exists about the role of Tyk2 in IL-
10-mediated signalling. Although no effect has been observed in earlier studies [32, 34], 
partially impaired responses to IL-10 were reported in Tyk2-deficient peritoneal 
macrophages more recently [39]. Interestingly, IL-10R2 and Tyk2 are likely also involved 
in type III IFN signalling, albeit direct evidence remains to be provided. Despite sharing 
the same receptor chain with the IL-10 family of cytokines, type III IFNs are more related 
to and exert similar biological functions as type I IFNs [40]. 
 
 
 
 
Figure 2: Cytokines and receptors that utilise Tyk2. Receptor complexes utilised by the IL-10 and gp130 
family of cytokines consist of a common and a cytokine-specific receptor chain (*, **). Additional 
cytokines (and their respective cytokine-specific chains) that signal via these common chains are 
for (*): e.g. IL-22 (IL-22R) and IFN$ (IL-28R1) and for (**) e.g.: LIF (LIFR), oncostatin M (OSMR) 
and IL-27 (WSX-1). Therefore, Tyk2 might also affect signalling by these cytokines.  
 
 
2.3.2.  Consequences of Tyk2 deficiency 
In order to analyse the functions of Tyk2, three Tyk2 knockout mice have been 
engineered independently from each other [32, 34, 41]. In addition, the B10.Q/J strain 
carries a naturally occurring mutation in the Tyk2 gene that was reported to result in the 
absence of Tyk2 protein [33]. Conflictingly, Tyk2 protein was detected in B10.Q/J mice 
very recently [42]. Tyk2-deficient mice are viable and fertile and do not show gross 
abnormalities in lymphocyte development and proliferation, but their innate and adaptive 
immune responses are impaired. Until now Tyk2-deficient mice have been challenged 
with a range of viral and bacterial pathogens and effects of Tyk2 in diverse disease 
models have been analysed. Tyk2 can be protective, neutral or even deleterious for the 
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host. Tyk2 is dispensable in the host defense against vesicular stomatitis virus (VSV). In 
contrast, prominent defects in cytotoxic T lymphocyte (CTL) activity following infection with 
lymphocytic choriomeningitis virus (LCMV), and elevated vaccinia virus (VV) replication in 
spleens of Tyk2-/- mice have been reported [32]. Strongly reduced survival and impaired 
clearance of virus from several organs of mice lacking Tyk2 were monitored after 
challenge with murine cytomegalovirus (MCMV) [43]. Tyk2-deficient mice are also highly 
susceptible to infections with the intracellular bacteria Listeria monocytogenes [44] and 
(as demonstrated with B10.Q/J mice) the protozoan parasite Toxoplamsa gondii [33, 45]. 
Tyk2 is differentially required for the defense against Leishmania major, as more severe 
and prolonged skin lesions develop in Tyk2-/- mice, but Tyk2 is not required for the 
ultimate control of the disease [46]. 
Apart from infectious diseases, Tyk2 involvement in several other disease models has 
been studied. For example, resistance of Tyk2-deficient mice against high-dose LPS-
induced [25, 47] and also intestinal ischemia/reperfusion-induced shock [48] could be 
shown. Moreover B10.Q/J mice are completely resistant to collagen-induced arthritis 
(CIA), an animal model for inflammatory polyarthritis [33]. Tyk2-mediated signalling plays 
a critical role in pathogenic CD4 T cell responses involved in the development of 
experimental autoimmune encephalomyelitis (EAE) [49]. Mice lacking Tyk2 show 
increased B lymphoid leukaemia/lymphoma formation and impaired tumour surveillance 
[50, 51]. Nonetheless, Tyk2-dependent invasiveness of malignant cells was reported in 
human prostate cancer cells in vitro [52] and more importantly, in a murine model system 
for human Burkitt’s lymphoma [53]. Tyk2-deficient mice exhibit a tendency towards Th2 
responses, as exemplified by the use of a mouse asthma model, resulting in enhanced 
allergic lung inflammation, increased antibody production and recruitment of eosinophils 
[54]. 
Intriguingly, loss of Tyk2 has been associated with distinct phenotypes in humans and 
mice and a patient who had been clinically diagnosed with hyper-IgE syndrome (HIES), 
turned out to carry a homozygous Tyk2 mutation. This patient displayed an unusual 
susceptibility to a number of microorganisms including virus, fungi and mycobacteria and 
suffered from atopic dermatitis. In contrast to previous data obtained in mice, almost 
complete defects in type I IFN, IL-6 and IL-10 signalling has been observed in this 
patients T cells, peripheral blood monocytes and macrophages, respectively. 
Transduction of a functional Tyk2 gene completely rescued cytokine signalling in T cells 
from this patient [54, 55]. Intriguingly, evidence for an implication of Tyk2 in human 
diseases, like multiple sclerosis (MS), psoriasis, systemic lupus erythematosus (SLE) and 
Crohn’s disease has been provided by genome-wide association studies [56-61]. 
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2.4. Signal transducers and activators of transcription (Stats) 
The seven mammalian Stat family members (Stat1-4, 5a, 5b and 6) largely reside in the 
cytoplasm of resting cells as inactive dimers. Stats range in size from 750 to 900 amino 
acids and constitute of seven structurally and/or functionally conserved domains. The 
amino-terminal domain is responsible for dimerisation of unphosphorylated Stats, 
whereas the adjacent coiled-coil domain associates with regulatory proteins. As indicated 
by its name, the DNA-binding domain (DBD) enables binding of Stats to DNA. The linker 
domain serves to achieve an appropriate conformation between the DNA-binding and the 
dimerisation domains. All of these domains have also been implicated in the regulation of 
nuclear import and/or export. The SH2 domain, which is the most highly conserved 
domain within the Stat family, mediates specific recruitment to receptor chains, and 
formation of active Stat dimers. In close proximity to the SH2 domain, the tyrosine 
activation motif is positioned, usually near residue 700, thereby precluding intramolecular 
SH2-phosphotyrosine association. The adjacent carboxy-terminal residues constitute the 
transcriptional activation domain (TAD), which varies considerably in length and sequence 
among different Stats. This divergence facilitates association with multiple transcriptional 
regulators and the TADs of all Stats (except Stat2) include conserved serine 
phosphorylation sites providing additional opportunities for regulation (see below). 
Intriguingly, a number of naturally occurring carboxy-terminally truncated Stat isoforms 
exist, i.e. Stat1!, Stat3!, and Stat4! [62-64]. The latter two of which have been shown to 
direct gene expression programs different to those mediated by their full-length 
counterparts (Stat3# and Stat4#) [65-68]. 
Apart from the canonical tyrosine phosphorylation, Stats can undergo additional covalent 
modifications, most notably serine phosphorylation. All Stats, with the exception of Stat2, 
can be phosphorylated on at least one serine residue in their TAD, and this promotes 
transcriptional activity [69-73]. Several additional, although poorly characterised, 
modifications that regulate Stat activity (e.g. acetylation and/or O-glycosylation, R-
methylation, SUMOylation and ubiquitin-directed decay of Stats) have been described. 
However, their roles are still partially controversial [28]. Recently, it has been found that 
Stats 1 and 3 (and probably other Stats) also play important roles in mediating gene 
expression without tyrosine phosphorylation [74, 75]. 
Stat1 knock-out mice exhibit profound defects in their biological response to type I and 
type II IFNs and consequently are highly susceptible to microbial infections [28]. 
Furthermore, Stat1-null mice displayed increased susceptibility to chemically induced and 
spontaneous tumours and Stat1 deficiency has also been linked to impaired growth 
control [63, 64]. In general, Stat1 target genes appear to promote inflammation and 
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antagonise proliferation [28]. Stat2 is mainly active in a complex together with Stat1 and 
IRF9, the ISGF3 and Stat2-deficient mice showed severe defects in their biological 
response to type I IFNs and loss of IFN I autocrine activity [27, 28]. Stat3 deficiency 
results in early embryonic lethality (E6.5-7.5) and this is consistent with the involvement of 
Stat3 in signal transduction downstream of a wide range of cytokines and growth factors. 
For example biochemical and genetic studies have revealed a pivotal role of Stat3 in 
transducing signals of the entire IL-6 and IL-10 families of cytokines. Tissue-specific 
knock-outs have highlighted an important anti-inflammatory role for Stat3, whereas many 
cancers have been associated with constitutively active Stat3 [27]. Stat4 knock-out mice 
elucidated a critical role of this transcription factor in IL-12 signalling. Therefore, Stat4-
deficient mice are not able to mount Th1 responses or activate NK cells and consequently 
show impaired IFN" secretion [27, 28]. Two tandem genes encode Stat5a and Stat5b. 
Stat5a-deficient mice displayed impaired mammary gland development owing to the loss 
of prolactin responsiveness, whereas deletion of Stat5b resulted in impaired growth due to 
the loss of growth hormone responsiveness. Deletion of the entire Stat5a-Stat5b gene 
locus has revealed a substantial role of Stat5 in erythropoiesis and lymphopoiesis [27, 
62]. Biochemical and genetic studies have demonstrated the importance of Stat5a and 
Stat5b in signalling of the IL-3, single chain and "c receptor families [28]. Stat6-null mice 
exhibited profound defects in Th2 cell polarisation due to impaired IL-4 and IL-13 
signalling. Furthermore Stat6 deficiency has been associated with impaired mast cell 
activation and B-cell function, including defects in proliferation, maturation, and MHC II 
and IgE expression [27, 28]. 
 
3. Interleukin-17 (IL-17) and the IL-17 family of cytokines 
IL-17 (also designated IL-17A) is the founding member of a novel cytokine family that has 
originally gained prominence due to its involvement in various autoimmune diseases in 
both men and mice. The mammalian IL-17 family comprises six members (IL-17A-F), 
amongst those IL-17F protein is most homologous to IL-17 (~50%). IL-17E (also known as 
IL-25) is most divergent and shares only 17% protein sequence similarity. Although 
cellular sources and expression patterns differ, all IL-17 cytokines have proinflammatory 
activities. Nevertheless, half of the IL-17 family members (IL-17B, IL-17C and IL-17D) are 
still poorly characterised and await future investigation [76]. 
Up until now IL-17 and IL-17F are the most intensively studied family members. Both form 
homodimers but also IL-17–IL-17F heterodimers. Homo- and heterodimers utilise the 
same receptor subunits for signalling, namely IL-17RA and IL-17RC, which together form 
heteromeric complexes. Although there is considerable overlap in their biological 
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functions, individual biological effects have been reported. IL-17 and IL-17F, as well as IL-
21 and IL-22 are the lineage-defining cytokines of T helper type 17 (Th17) cells, the most 
recently discovered Th cell lineage [76-78]. Th17 cells are considered particularly 
important in host defense against bacterial, mycobacterial and fungal pathogens, 
especially at epithelial surfaces. However, Th17 functions extend beyond protection 
against extracellular pathogens, as demonstrated by infections with a number of 
intracellular bacteria. Like other effector T cells, dysregulated Th17 cells can cause 
immunopathology and they have been implicated in organ-specific and systemic 
autoimmune diseases like psoriasis, rheumatoid arthritis and multiple sclerosis, and also 
in animal models like EAE and CIA [79]. Moreover, it has become apparent that Th17 
responses can also contribute to viral persistence and chronic inflammation associated 
with parasitic infection [80]. In mouse tumour models and in human cancers it has been 
shown that Th17 cells and associated cytokines have both anti- and pro-tumourigenic 
functions [81, 82]. 
Th17 cells depend on a specific cytokine milieu, composed of IL-6, TGF! and, only in 
humans, IL-1! for their development from naïve T cells to effector T cells, while IL-23 is 
important for their maintenance. IL-21 drives Th17 development via a positiv feedback 
loop. Additionally, several specific transcription factors (Stat3, ROR"t and ROR#) are 
critically involved in Th17 development [83].  
IL-17 and IL-17F induced signalling is mediated by Act1 (also known as CIKS), TRAF6 
and NF-%B [78]. However, Act1-independent pathways are also induced, since ERK1 and 
ERK2 are activated in Act1-/- cells in response to IL-17, albeit with delayed kinetics [84]. 
Although IL-17 induces the activation of various MAPKs, ERK is generally most strongly 
and rapidly phosphorylated. Interestingly, pharmacological inhibitors of Jaks have been 
reported to limit IL-17-mediated signalling and weak activation of Stats and PI3K have 
also been shown [78]. 
IL-17 triggers downstream production of a number of proinflammatory cytokines (e.g. IL-6, 
IL-1! and TNF#), chemokines and metalloproteinases in various cell types, thereby co-
ordinating neutrophil expansion, survival, and early recruitment to local sites of infection 
[79]. Additionally, target genes that have chemotactic activity for lymphocytes, DCs and 
other immune cells, as well as monocyte-recruiting chemokines are induced by IL-17. 
Direct killing of invading organisms is warranted by the upregulation of antimicrobial 
peptides and notably, some chemokines that also exhibit antimicrobial activity. 
Besides being produced by Th17 cells, both IL-17 and IL-17F production by a growing 
number of cell types has been reported [83, 85]. For example, IL-23–dependent IL-17 
production by "& T cells has been detected in mice following infection with Escherichia 
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coli, Mycobacterium tuberculosis or Mycobacterium bovis [86-88]. It has also been 
demonstrated that IL-1! and IL-23 induced IL-17 expression in "& T cells independent of 
TCR engagement [89]. Peritoneal NK cells isolated from Toxoplasma gondii infected mice 
were shown to produce IL-17 in an IL-6–, IL-23– and TGF-!–dependent manner [90]. 
Invariant natural killer T (iNKT) cells and NKT cells secreted IL-17 either after TCR or  
IL-23R ligation, and engagement of both receptors has a synergistic effect. Unlike NK and 
naïve T cells, NKT and iNKT cells constitutively express IL-23R and ROR"t [91-93]. In a 
mouse model of LPS-induced lung inflammation IL-17 secretion by neutrophils has been 
observed [94]. IL-17 was also secreted by eosinophils in the bronchoalveolar lavage from 
asthmatic patients [95]. However, in a mouse model mimicking allergic asthma, alveolar 
macrophages have been identified as the main source of IL-17 [96]. Interestingly, TLR2-
dependent IL-17 production has been detected in murine peritoneal macrophages after 
treatment with Porphyromonas gingivalis LPS but not after challenge with live bacteria 
[97]. Furthermore, IL-17 expression by IL-10–deficient peritoneal macrophages has been 
demonstrated in response to E. coli LPS [98]. Stimulation with IL-23 or the TLR2 agonist 
zymosan, rapidly induced IL-17 production in lymphoid tissue inducer-like (LTi-like) cells, 
which was impaired in the absence of Stat3. These cells constitutively express the IL-23R, 
aryl hydrocarbon receptor (AHR) and CCR6 [99]. In a model of TNF-induced shock IL-17 
was rapidly secreted by Paneth cells, which are highly specialised epithelial cells in the 
gut [100]. 
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AIMS 
 
The Janus kinase family member tyrosine kinase 2 (Tyk2) participates in numerous 
cytokine and growth factor signalling pathways. We and others have shown that  
Tyk2-/- mice have defects in the antiviral defense against selected viruses and are more 
susceptible to various other pathogens. In contrast, Tyk2-/- mice are resistant to lipopoly-
saccharide(LPS)-induced endotoxin shock. Most of the defects described so far could be 
attributed to impaired IL-12 signalling and consequently, reduced IFN" production, and to 
partial defects in IFN#/! responses. 
In ongoing transcriptomics and proteomics studies comparing wildtype with Tyk2-/- 
macrophages, several genes/proteins were identified that showed Tyk2-dependent 
regulation in response to LPS. The first aim of my thesis was to further characterise a 
selection of these genes/proteins with respect to the kinetics of induction and the 
molecular mechanisms involved. The second major goal was to investigate the in vivo 
relevance of these findings. For this purpose, I focussed on gene induction in vivo, organ 
specificity and cell type distribution of the most interesting target gene(s)/protein(s). Based 
on the findings, further in depth in vitro analysis should be conducted in additional primary 
cell types (e.g. T cells, NK cells, DCs).  
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RESULTS I 
 
Tyrosine kinase 2 is required for LPS-induced IL-17 production in inflammatory 
macrophages and spleens 
 
Stiefvater et al., manuscript in preparation 
 
 
!30
 
 
 31
 
TYROSINE KINASE 2 (TYK2) IS REQUIRED FOR LPS-INDUCED IL-17 PRODUCTION 
IN INFLAMMATORY MACROPHAGES AND SPLEENS 
Rita Stiefvater1, Elisabeth Hofmann1, Thomas Kolbe2,3, Ursula Reichart1, Caroline 
Lassnig1,2, Claus Vogl1, Valeria Poli4, Mathias Müller1,2 and Birgit Strobl1,5 
 
1
Institute of Animal Breeding and Genetics, University of Veterinary Medicine, Vienna, Austria; 
2
University Center Biomodels Austria, University of Veterinary Medicine, Vienna, Austria; 
3
Institute of Biotechnology in Animal Production, Department IFA-Tulln, University of Natural Resources and Applied Life 
Sciences, Tulln, Austria; 
4
Department of Genetics, Biology and Biochemistry, Molecular Biotechnology Center, University of Turin, Turin, Italy. 
 
5
corresponding author 
 
 
Abstract 
 
The Janus kinase (Jak) family member tyrosine kinase 2 (Tyk2) is an integral part of 
various cytokine and growth factor signalling pathways. We have previously reported that 
macrophages from Tyk2-deficient mice fail to fully respond to lipopolysaccharide (LPS). 
We demonstrate herein, that LPS stimulation induces interleukin-17 (IL-17) production via 
a Tyk2-dependent pathway in thioglycollate-elicited peritoneal macrophages. IL-17 and IL-
17F are upregulated upon LPS treatment with similar kinetics and both mRNAs are 
considerably reduced in the absence of Tyk2. Induction of IL-17 and IL-17F is only slightly 
reduced in type I interferon (IFN!/") receptor 1 (Ifnar1) deficient macrophages, 
demonstrating that auto-/paracrine actions of IFN!/" do not strongly impact on IL-17 
production in macrophages. Interestingly, signal transducer and activator of transcription 3 
(Stat3) is not required for LPS-induced IL-17 production in macrophages. In the absence 
of Stat3, IL-17 and IL-17F mRNA and IL-17 protein are already produced constitutively 
and are strongly increased upon LPS treatment. Thus, in contrast to its essential role in 
the differentiation/maintenance of IL-17 producing T cells (Th17), Stat3 in macrophages 
exerts inhibitory rather than stimulatory effects on LPS-induced IL-17 production. We 
furthermore show that Tyk2 is indispensable for splenic IL-17 production following 
intraperitoneal LPS administration in vivo. However, we did not find evidence for a 
substantial contribution of CD11b+ cells to the early IL-17 production. Instead, #$ T cells 
and, to a lesser extent, plasmacytoid dendritic cells (pDCs) appear to be the main sources 
of innate IL-17 in spleens. Taken together we show a crucial role of Tyk2 for LPS-induced 
innate IL-17 production in vitro and in vivo. 
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Introduction 
 
A large number of cytokines transduce their signals via the Janus kinase (Jak) - signal 
transducer and activator of transcription (Stat) signalling pathway [1, 2]. Tyrosine kinase 2 
(Tyk2) is one of the four mammalian Jak family members and has been initially identified 
via its critical role in type I interferon (IFN!/") signalling [3]. Tyk2 activation has been 
subsequently demonstrated for gp130-receptor chain-utilising cytokines, interleukin (IL)-
10, IL-12, IL-13, IL-22 and IL-23 [4-6]. Cells from Tyk2-deficient mice show selective and 
partial defects in cytokine responses and Tyk2 deficiency leads to increased susceptibility 
to a number of different pathogens [7-12]. On the contrary, Tyk2-/- mice are resistant to 
high-dose lipopolysaccharide (LPS)-induced endotoxin shock [13, 14]. LPS signals 
through Toll-like receptor 4 (TLR4) and evokes various cell signalling pathways [15-17]. 
The induction of proinflammatory cytokines, like tumour necrosis factor ! (TNF!) and IL-
1", occurs through the activation of the nuclear factor-%B (NF-%B) pathway via the adaptor 
molecule myeloid differentiation factor 88 (MyD88). MyD88-independent activation of 
interferon regulatory factor 3 (IRF3) induces expression of IFN", which subsequently 
leads in an auto-/paracrine way to the induction of numerous IFN-responsive genes. In 
addition, IFN!/" can amplify its own expression via the induction of IRF7 in the presence 
of activating stimuli [18]. Tyk2-deficient macrophages show impaired IFN!/"  and 
inducible nitric oxide synthase (iNOS, NOS2) expression in response to LPS, while the 
production of TNF! remains unaffected [14]. This phenotype may be caused by reduced 
basal and induced availability of transcription factors in the absence of Tyk2, i.e. Stat1, 
IRF1 and IRF7 [8, 14], but the exact mechanisms are not clear to date. 
IL-17 (also designated IL-17A) is the prototype of the IL-17 family, which consists of six 
members (IL-17A–F). Amongst those, IL-17F is most homologous to IL-17 and 
considerably overlapping yet distinct biological functions have been reported [19-21]. IL-
17 is currently classified as proinflammatory cytokine, as it induces a number of mediators 
including those involved in chemotaxis of neutrophils. The T helper type 17 (Th17) cell 
lineage is considered to be the major source of IL-17, especially in autoimmune diseases, 
but also in immunity to infection [22]. In addition IL-17F, IL-22 and IL-21 are preferentially 
produced by this T cell subset [23, 24]. Transforming growth factor " (TGF-") and IL-6 
have been shown to drive Th17 development [25-27], whereas subsequent exposure to 
IL-23 and IL-1" is necessary for full effector differentiation and function [25, 28-31]. 
Furthermore, IL-23 mediated proliferation and IL-17 production have been reported in 
memory T cells [32, 33]. Only recently, more attention has been paid to IL-17 production 
and underlying mechanisms in innate immune responses. It has been demonstrated that 
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IL-17 can be rapidly produced by innate immune cells like #$ T cells, iNKT cells, lymphoid 
tissue inducer (LTi)-like cells and macrophages [34-38]. It has become clear, however, 
that although these cell populations share some common activating signals (e.g. IL-23, IL-
23R, ROR#t), unique yet ill-defined pathways are involved [39].  
In this study we show that IL-17 mRNA and protein production in response to LPS are 
dependent on the presence of Tyk2 but independent of functional IFN!/" signalling in 
murine inflammatory peritoneal macrophages. We define a negative regulatory role for 
Stat3, as myeloid-specific Stat3 deletion results in enhanced IL-17 production. The 
importance of Tyk2 for LPS-induced IL-17 production is confirmed in vivo. Although #$ T 
cells appear to be the major source of innate IL-17 production in spleens, we provide for 
the first time evidence for the ability of pDCs to produce IL-17 and exclude a substantial 
contribution of CD11b+ cells. 
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Materials and Methods 
 
Mice 
All mice were on C57BL/6 background. Tyk2-/-, Ifnar1-/- and Stat3fl/fl mice were described 
previously [8, 40, 41] and were backcrossed over 10 generations into C57BL/6. LyzsCre 
(also designated LysMCre) mice were purchased from the Jackson Laboratory, 
Sacramento, CA (strain name: B6.129P2-Lyzstm1(cre)Ifo/J) and crossed with Stat3fl/fl mice to 
generate Stat3LyzsCre-/- mice. This strain expresses Cre recombinase from the endogenous 
Lyzs locus. Cre-mediated recombination results in deletion of the loxP site-flanked Stat3 
gene in the myeloid cell lineage (including monocytes, mature macrophages, and 
granulocytes). Mice were housed under specific pathogen-free conditions according to 
FELASA guidelines. All animal experiments were discussed and approved by the 
institutional ethics committee and conform with Austrian laws (BM.W_Fa ref. 68.205/0204-
C/GT/2007 and ref. 68.205/0233-II/10b/2009). 
 
Isolation of cells and LPS challenge 
Thioglycollate-elicited peritoneal macrophages were prepared and cultured in DMEM 
(supplemented with 5 % FCS, 100 !g/ml penicillin, 100 U/ml streptomycin, 1 mM  
L-glutamine and 50 !M 2-mercaptoethanol) as described previously [42]. Macrophages 
were stimulated approximately 24 h after isolation with 100 ng/ml LPS (E. coli serotype 
055:B5; Sigma-Aldrich, St. Louis, MO; dissolved in PBS) for the times indicated. Age- (8-
10 weeks) and sex-matched mice were injected i.p. with LPS (1 mg per 20 g body weight). 
To assess in vivo intracellular IL-17 levels, 0.25 mg Brefeldin A (Sigma-Aldrich) was 
simultaneously injected i.v., as previously described [43]. At the indicated times mice were 
sacrificed. Single cell suspensions were prepared from spleens of LPS-challenged and 
control mice. Splenocytes were incubated with MACS beads conjugated with anti-Dx5, 
anti-CD11b, anti-CD19 and anti-PDCA1. Cells were purified by positive selection using 
MACS columns following the manufacturer’s protocol (Miltenyi Biotec, Bergisch Gladbach, 
Germany). 
 
Antibodies 
Anti-phospho-Stat3, anti-Stat3, anti-phospho-p44/p42 MAPK (ERK1, ERK2), anti-
phospho-Akt, anti-Akt and anti-phospho-NF-%B-p65 antibodies (Abs) were purchased 
from Cell Signaling Technologies (Danvers, MA); anti-pan-ERK from BD Biosciences (San 
Diego, CA)  and anti-NF-%B-p65 Ab from Upstate Biotechnology (Lake Placid, NY). Pacific 
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Blue-conjugated anti-CD3 (17A2) Ab was from BioLegend (San Diego, CA), PE-
conjugated anti-IL-17 (TC11-18H10) and FITC-conjugated anti-TCR#$ (GL3) from BD 
Biosciences. AlexaFluor® 647-conjugated Siglec-H (eBio440c) was purchased from 
eBioscience (San Diego, CA). 
 
Cell lysis, Western blot analysis 
Cells (2x106) were lysed in 10 mM Tris-HCl (pH 8.0), 150 mM NaCl, 0.5 % Igepal CA-630 
(v/v), 10 % glycerol (v/v), 1 mM DTT, 0.1 mM EDTA, 1 mM sodium orthovanadate, 25 mM 
sodium fluoride, 3 !g/ml aprotinin, 1 !g/ml leupeptin, and 1 mM PMSF. Cell debris was 
removed by centrifugation, and whole-cell lysates were used for Western blot analysis. 
10 !g of whole-cell lysates were separated on 6.5 % or 10 % SDS-polyacrylamide gels 
and transferred onto nitrocellulose membranes. Membranes were probed using the 
indicated Abs and the ECL detection system (GE Healthcare, Munich, Germany). 
 
Quantitative RT-PCR (qRT-PCR) 
Total RNA was isolated using TRIzol (Invitrogen Life Technologies, Lofer, Austria), and 
reverse transcribed using the iScript cDNA Synthesis Kit (Bio-Rad Laboratories, Vienna, 
Austria) each according to the manufacturer’s instructions. The standard 20 !l reaction 
contained 1x PCR buffer (Reaction buffer B, Solis BioDyne, Tartu, Estonia), 200 !M 
dNTP, 4 mM MgCl2, 300 nM primers, 100 nM probe, 1U HOT FIREPol (Solis BioDyne). 
For IL-17 (IL-17A) and IL-17F TaqMan Gene Expression Assays (Applied Biosystems by 
Life Technologies, Carlsbad, DA, assay IDs Mm00439619_m1 and Mm00521423_m1, 
respectively) were used for cDNA amplification. Primers and probes for Ube2d2 and 
TNF! were submitted to the Real-Time PCR Primer and Probe Database 
(http://medgen.ugent.be/rtprimerdb/; RTPrimerDB identification numbers 3377 and 3747, 
respectively [44]). IL-17, IL-17F and Ube2d2 qRT-PCRs were conducted with an ABI 
PRISM 7900HT Sequence Detection System (Applied Biosystems). TNF! qRT-PCR was 
conducted with a Mastercycler realplex (Eppendorf, Vienna, Austria). All assays were 
performed under the same cycling conditions: 15 min at 95°C, 20 s at 95°C and 1 min at 
60°C; steps 2 and 3 were repeated 40 cycles (TNF!, Ube2d2) or 45 cycles (IL-17, IL-
17F). Fluorescence data were collected during the extension phase (step 3). Differential 
target gene expression was calculated as previously described [14], using Ube2d2 as 
endogenous control. With the exception of MACSed spleen cells, n-fold expression levels 
were calculated relative to the untreated wildtype (WT 0h). Target gene expression in 
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MACSed spleen cells was normalised to the endogenous control (Ube2d2) and multiplied 
with 1000. 
 
Measurements of cytokines 
Cell culture supernatants were collected and centrifuged at 5000 ! g for 3 min. IL-17 and 
IL-17F concentrations were determined by ELISA (R&D Systems, Minneapolis, MN; 
detection limit 10 pg/ml). 
 
Intracellular cytokine staining and flow cytometric analysis 
Single cell suspensions were prepared from spleens of LPS-challenged and control mice 
(all treated with Brefeldin A). Splenocytes were incubated with MACS beads conjugated 
with anti-CD19. Cells were depleted using MACS columns following the manufacturer’s 
protocol (Miltenyi Biotec). Cell surface markers were stained with appropriate antibodies 
for 30 min at 4°C. Thereafter, intracellular staining was performed according to 
manufacturer’s instruction (BD Biosciences). Briefly, 100 !l of BD Cytofix/Cytoperm 
solution (BD Biosciences) was added to cell suspension with mild mixing and incubated 
for 20 min at 4°C. Fixed cells were washed twice with 250 !l of BD Perm/Wash solution 
(BD Biosciences) and were stained intracellularly with PE-conjugated anti-mIL-17 mAb for 
30 min at 4°C. Stained cells were analysed on a flow cytometer (FACSAria; BD 
Biosciences). Events were collected and analysed with FACSDiva software (BD 
Biosciences). 
 
Statistical analysis 
qRT-PCR gene expression data were investigated for differences among genotypes and 
time after challenge. Univariate regression was calculated with the log-transformed target 
to control gene ratio as dependent variable. Linear contrasts were encoded using dummy 
variables, such that i) for each time point the mutant genotypes were compared to the 
wildtype and ii) for each time point the mutant genotypes were compared to each other. In 
both cases, differences among experiments were taken into account. Analysis of ELISA 
data was performed using log-transformed data. As above linear contrasts were encoded 
using dummy variables such that genotypes were compared after 24 h of treatment. 
Analysis was done using SPSS 13 for Mac OS-X. For the evaluation of FACS data of 
single treatments/time points chi-squared tests were applied (R: a language and 
environment for statistical computing, http://www.R-project.org). 
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Results 
 
IL-17 and IL-17F expression is induced by LPS in macrophages in a Tyk2-dependent and 
Ifnar1-independent manner 
In order to further elucidate the impact of Tyk2 deficiency on LPS responses, we have 
conducted a qRT-PCR screening experiment and found IL-17F as Tyk2-dependent, LPS 
induced gene (E. Hofmann, unpublished data). In addition to IL-17F, we also found Tyk2 
dependence for IL-17 induction in macrophages (Fig. 1A). IL-17 mRNA was rapidly and 
strongly induced by LPS. Induction could already be observed 1 h following treatment and 
peaked around 6 to 8 h. IL-17 mRNA expression was dependent on the presence of Tyk2 
at all time points investigated. In the absence of the IFN!/" receptor 1 (Ifnar1), IL-17 
induction occurred slightly delayed but reached similar mRNA levels as in wildtype cells at 
later time points. Detailed analysis of IL-17F mRNA expression revealed a similar 
transient induction and mRNA levels peaked at the same time but with a slightly higher 
amplitude than observed for IL-17 (Fig. 1B). Dependency on Tyk2 and induction in the 
absence of Ifnar1 was similar for IL-17 and IL-17F. In contrast, and consistent with 
previous data on TNF! protein secretion in Tyk2-/- macrophages [14], TNF! mRNA 
induction occurred independently of Tyk2 and Ifnar1 (Fig. 1C). We next examined whether 
IL-17 and IL-17F protein is secreted by macrophages. IL-17 in cell culture supernatants 
reached about 60 pg/ml on average at 24 h after LPS treatment (Fig. 1D). In the absence 
of Ifnar1, secretion was modestly but significantly lower than in wildtype cells and severely 
impaired in Tyk2-/- macrophages (Fig. 1D). Similar results were obtained for IL-17F 
(Fig. 1E). Thus, although IFN!/" signalling can inhibit IL-17 production under certain 
conditions [45, 46], auto-/paracrine IFN!/" acts modestly enhancing in LPS-treated 
macrophages. Of note, overall IL-17 protein levels were quite low but consistent with 
previous reports on LPS-treated macrophages [47, 48]. Comparable IL-17 amounts were 
also secreted by peritoneal macrophages in response to chitin [49] and by alveolar 
macrophages following exposure to supernatants derived from OVA/IgE-stimulated mast 
cells [50].  
 
LPS-mediated Stat3 activation is impaired in the absence of Tyk2  
Stat3 has been implicated in the development of IL-17–producing T cells [51, 52] and 
direct binding of Stat3 to the IL-17 and IL-17F promoters has been postulated [51]. We 
thus analysed the dependence of Stat3 tyrosine phosphorylation on Tyk2 in response to 
LPS. Stat3 phosphorylation could first be detected after 2 h LPS treatment, declined at 4 h 
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and was detectable for up to 12 h after treatment (Fig. 2A and data not shown). Stat3 
phosphorylation was strongly dependent on the presence of Tyk2 at all time points 
investigated (Fig. 2A and data not shown). Apart from Stat3, the PI3K/Akt and NF-%B 
pathways have been implicated in the induction of IL-17 expression under certain 
conditions [53, 54]. As shown in Fig. 2B, Akt serine phosphorylation upon LPS treatment 
was relatively low in our experimental setup and clearly not affected by the absence of 
Tyk2. Similarly, LPS-induced activation of NF-%B was not dependent on Tyk2 (Fig. 2C). 
This is in accordance with previous findings showing unperturbed I%B degradation in 
Tyk2-deficient macrophages [14] and further underscores the redundant role of Tyk2 in 
the activation of the MyD88/NF-%B pathway. 
 
Stat3 plays an inhibitory role for the induction of IL-17 by LPS 
Given the reduced Stat3 activation observed in the absence of Tyk2, we examined the 
role of Stat3 for LPS-mediated IL-17 induction. For that purpose we used macrophages 
derived from Stat3fl/flLyzsCre (Stat3Lyzs-/-) mice that lack Stat3 specifically in myeloid cells 
(i.e. macrophages and neutrophils). Surprisingly, IL-17 and IL-17F mRNA induction were 
strongly increased in cells from Stat3Lyzs-/- mice (Fig. 3A and 3B). Notably, even basal 
levels of both IL-17 and IL-17F mRNA were more than 10-fold higher in cells from 
Stat3Lyzs-/- mice as compared to Stat3fl/fl. Enhanced TNF! production upon LPS treatment 
has been reported in macrophages from mice with a similar conditional Stat3 deletion [55] 
and this is attributable to a well-established impaired IL-10 response in the absence of 
Stat3 [56, 57]. However, under our experimental conditions, TNF! mRNA was induced 
similarly in macrophages derived from Stat3fl/fl or Stat3Lyzs-/- mice, respectively (Fig. 3C). In 
line with IL-17 mRNA expression data, IL-17 protein secretion was increased in cells 
derived from Stat3Lyzs-/- mice (Fig. 3D). Remarkably, constitutive IL-17 secretion in cells 
derived from Stat3Lyzs-/- mice reached similar levels as in LPS-treated cells derived from 
Stat3fl/fl (Fig. 3D) or wildtype (Fig. 1D) mice. Increased IL-17 expression was not due to a 
generally increased LPS response, since neither ERK1/2 nor NF-%B were constitutively 
active and their LPS-mediated activation was similar in cells derived from Stat3fl/fl or 
Stat3Lyzs-/- mice, respectively (data not shown).  
 
IL-17 mRNA expression is reduced in the absence of Tyk2 following LPS challenge in vivo 
To investigate whether IL-17 production is similarly dependent on Tyk2 in vivo, we 
injected wildtype, Tyk2- and Ifnar1-deficient mice intraperitoneally (i.p.) with LPS and 
examined IL-17 mRNA expression in spleens. As shown in Fig. 4A IL-17 mRNA levels 
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were 1000-fold increased in WT mice 12 h and 18 h following LPS challenge, and similar 
levels were detected in the absence of Ifnar1. In contrast, IL-17 mRNA expression was 
strongly reduced in Tyk2-deficient spleens at both time points analysed. Thus, analogous 
to what we found in macrophages, IL-17 mRNA expression was highly dependent on Tyk2 
but independent of Ifnar1 in spleens. Since we additionally evidenced an inhibitory role of 
Stat3 for IL-17 production in macrophage cultures we tested whether Stat3 in myeloid 
cells likewise inhibits IL-17 production in vivo. We injected Stat3fl/fl and Stat3Lyzs-/- mice i.p. 
with LPS and quantified IL-17 mRNA expression in spleens. Although mRNA levels of IL-
17 were modestly increased in Stat3Lyzs-/- compared to Stat3fl/fl mice, it was not statistically 
significant (Fig. 4B). Thus, unlike IL-17 production in peritoneal macrophage cultures, 
LPS-mediated IL-17 expression in spleens is not inhibited by myeloid Stat3. 
 
IL-17 mRNA levels are not affected by the absence of mature T- and B-cells 
We next examined the possibility that Th17 cells are responsible for IL-17 production after 
LPS challenge in vivo. Therefore, WT and Rag2-deficient mice, which lack mature T and 
B cells were challenged with LPS. As shown in Fig. 4C the level of IL-17 mRNA in spleens 
of untreated Rag2-deficient mice was 10-fold increased as compared to WT mice. 
Interestingly, following LPS challenge similar IL-17 mRNA levels were reached in WT and 
Rag2-/- mice. From these data we conclude, that neither mature T nor B cells are required 
for IL-17 production in response to LPS. 
 
CD11b+ cells do not substantially contribute to IL-17 mRNA expression in spleens after 
LPS challenge in vivo 
In order to determine if macrophages produce IL-17 in vivo, we enriched cells by magnetic 
cell sorting for specific markers and determined IL-17 mRNA expression in these cell 
populations from LPS-challenged WT mice. Since NK cells also express CD11b, albeit to 
a lower extent, we depleted DX5+ cells prior to the selection for CD11b-expressing cells. 
CD19+ cells were selected as negative control, as at least to our knowledge B cells do not 
produce IL-17. As shown in Fig. 5A, low levels of IL-17 mRNA were found in DX5+ and 
CD11b+ cells, whereas IL-17 mRNA was hardly detectable in CD19+ cells. However, only 
the flow population, i.e. DX5-, CD11b-, and CD19-depleted cells, displayed an increase in 
IL-17 mRNA expression relative to the expression levels determined in the total 
splenocyte population. In contrast, IFN# mRNA was specifically increased in DX5+ 
splenocytes relative to the levels in total spleen cells and was barely detectable in other 
populations (Fig. 5B). This is in accordance with previous reports identifying NK cells as 
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the major IFN#-producing cell type in response to LPS treatment [58, 59]. Interestingly, IL-
17 mRNA was also clearly detectable in cells selected for mPDCA1 (Fig. 5C), indicating a 
contribution of pDCs to splenic IL-17 production. However, mPDCA1– cells expressed 
clearly higher levels of IL-17 mRNA. As expected, IFN# mRNA expression was higher in 
mPDCA1-depleted cells, but substantial amounts were also produced in cells selected for 
mPDCA1 (Fig. 5D). Importantly, IL-17 and IFN# mRNA were barely detectable in 
mPDCA1+ and mPDCA1– cells derived from Tyk2-/- mice. Neither IL-17 nor IFN# mRNA 
was detectable in any of the selected populations of untreated mice (data not shown). In 
summary, these data indicated that CD11b–DX5–CD19– and mPDCA1– cells are the major 
IL-17 producers in spleens from LPS-treated WT mice, whereby mPDCA1+ cells might 
also contribute.  
 
"# T cells and pDCs are the major sources of IL-17 in response to LPS in vivo 
In order to confirm the results obtained with magnetic cell sorting and to further define the 
cell types involved, we next determined IL-17 protein producing cells by flow cytometry. 
CD19-depleted spleen cells of untreated and LPS-challenged WT mice were intracellularly 
stained for IL-17 in combination with various cell surface markers. We found a significant 
increase (around 2-fold) in IL-17+CD3–Siglec-H+ cells upon LPS-treatment (Fig. 6A). 
Siglec-H was shown to be highly specific for pDCs [60]. Importantly, analysis of the pDC 
population utilising distinct markers (i.e. CD3–CD4+B220+CD11cdim) revealed similar 
results (data not shown). In addition to Siglec-H+ cells, we found LPS-induced IL-17 
production in CD3+TCR#$+ cells (Fig. 6B). This population represents #$ T cells and 
showed a more pronounced increase in % positive cells than Siglec-H+ cells (around  
4-fold) (Fig. 6A and B). We could not detect any IL-17 and DX5 or CD11b double positive 
cells (data not shown). 
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Discussion 
Although IL-17 production has been mainly described in the context of Th17 cells, 
numerous studies reported IL-17 production by non-Th17 cells, e.g. CD8+ T cells and 
various subsets of innate immune cell populations [39, 61]. However, the mechanism(s) of 
IL-17 induction in these cells and their involvement in IL-17 production in vivo remain 
largely elusive. In this report we demonstrate that Tyk2 is indispensable for LPS-induced 
IL-17 production in peritoneal macrophage cultures and in spleens in vivo. We show that 
#$ T cells are the main source of IL-17 in spleens and demonstrate for the first time that 
pDCs contribute to IL-17 production in the early LPS response in vivo.  
Our data showing IL-17 production by murine peritoneal macrophages in response to LPS 
are in accordance with previous studies [38, 47]. Although the mechanism of IL-17 
induction in macrophages is unclear to date, it has been shown that many innate immune 
cells can directly respond to IL-23 and express the transcription factor ROR#t [39]. Stat3 
has been shown to be critically involved in both, IL-23 mediated signalling and regulation 
of ROR#t expression [52, 62-65]. We show here reduced activation of Stat3 and 
decreased IL-17 and IL-17F production in Tyk2-deficient as compared to wildtype 
macrophages following LPS treatment. Interestingly, we found enhanced IL-17 and IL-17F 
production upon LPS treatment in macrophages derived from mice with a Stat3 deletion in 
myeloid cells, as compared to cells derived from Stat3fl/fl mice. Thus, our data illustrate a 
Tyk2-dependent but Stat3-independent pathway for LPS-mediated IL-17 and IL-17F 
production, thereby excluding the contribution of an impaired IL-23/Stat3 axis to the 
phenotype observed in Tyk2-deficient macrophages. In addition, treatment with 
exogenous IL-23 was not sufficient to induce IL-17 (data not shown). In contrast to the 
crucial role of Stat3 for IL-17 production in T cells, we propose a Stat3-dependent 
negative regulatory pathway acting on IL-17 and IL-17F gene induction in macrophages. 
This might be due to the role of Stat3 in IL-10 signalling [56], since enhanced levels of  
IL-17 have been reported in IL-10-deficient macrophages following LPS treatment [47]. It 
is notable, that IL-17 and IL-17F basal mRNA expression are already significantly 
increased in cells derived from mice with a Stat3 deletion in myeloid cells and thus the 
effect is not strictly LPS-dependent. 
In contrast to peritoneal macrophages, we could not detect IL-17 and IL-17F mRNA or 
protein in bone marrow-derived macrophages (data not shown) and airway macrophages 
treated with LPS in vitro failed to produce detectable amounts of IL-17 mRNA [66]. This 
would suggest that the ability to respond to LPS with IL-17 and IL-17F production is 
dependent on the macrophage differentiation and/or activation state. However, we can not 
exclude the possibility that minor amounts of other cell types present in our macrophage 
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cultures [9] contribute to or are required for IL-17 and IL-17F production, as we were not 
able to detect intracellular IL-17 in peritoneal macrophage cultures by FACS analysis.  
Over the last years it has become increasingly evident that innate immune cells, most 
prominently #$ T cells and LTi-like cells, are critically involved in IL-17 production in vivo 
[37, 67]. It is known that #$ T cells are an important source of IL-17 following infections 
with various bacteria [45, 68, 69]. The importance of Tyk2 for IL-17 production by 
peritoneal #$ T cells following E. coli infection has been shown recently [70]. We report 
herein drastically reduced IL-17 levels in the absence of Tyk2 in spleens of LPS-
challenged mice, thereby providing new evidence for an essential role of Tyk2 in innate 
IL-17 production. Consistent with our results in peritoneal macrophage cultures, IL-17 
mRNA expression in vivo is independent of Ifnar1. Conversely, augmented IL-17 
production has been reported in #$ T cells in the spleens of Ifnar1-/- mice following 
infection with Francisella tularensis or Listeria monocytogenes [45]. Thus, the potential of 
IFN!/" to inhibit IL-17 production is context-dependent and it has to be determined if this 
is due to differences in the amounts of IFN!/", kinetics of induction and/or cell type 
specificity.  
Despite the dramatically increased IL-17 production observed in peritoneal macrophages 
derived from Stat3Lyzs-/- mice, only a slight and not significant increase in IL-17 mRNA 
levels was observed in spleens of Stat3Lyzs-/- mice upon LPS challenge. This further 
underscores the context dependence and complexity of regulatory networks controlling  
IL-17 production in vivo. 
We show that #$ T cells are the main source of IL-17 in spleens following LPS challenge, 
further emphasising their crucial role for innate IL-17 production. In addition, we show 
herein that splenic pDCs are capable of IL-17 production in response to LPS. We detect 
high levels of IL-17 mRNA in splenocyte subpopulations enriched for the expression of the 
pDC marker mPDCA1 [71] and IL-17 protein expression by FACS analysis in cells 
expressing the highly specific pDC marker Siglec-H [60, 72] and, additionally, by gating for 
CD3–CD4+B220+CD11cdim cells (data not shown). Thus, we suggest that in contrast to 
conventional DCs (cDCs), which drive Th17 differentiation [23, 73], pDCs per se are an 
early source of IL-17. Although #$ T cells apparently dominate the IL-17 production in 
spleens, the contribution of pDCs has to be taken into account. Importantly, IL-17 
production is dependent on Tyk2 in mPDCA1+ and mPDCA1– splenocytes. Noteably, we 
did not find any evidence for substantial IL-17 production by macrophages in spleens of 
LPS-challenged mice. Similarly, IL-17 mRNA was not detectable in macrophages isolated 
from bronchoalveolar fluid after intranasal LPS application [74]. 
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In summary, we have characterised for the first time LPS-induced requirements for the 
production of IL-17 and IL-17F in murine peritoneal macrophage cultures and in spleens. 
We show that Tyk2 exerts an essential function in response to LPS independent from its 
role in the IFN!/" signalling cascade. We establish a negative regulatory role of myeloid 
Stat3 in the induction of IL-17 production in peritoneal macrophage cultures as opposed to 
its positive regulatory role in the generation and maintenance of IL-17–producing T cells. 
We confirm the importance of #$ T cells for innate IL-17 production and provide for the first 
time evidence for a contribution of pDCs to IL-17 production in spleens following LPS 
challenge. The further characterisation of the mechanism by which Tyk2 facilitates IL-17 
production in vivo as well as the physiological importance of pDC-derived IL-17 will be 
interesting topics for future investigations. 
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Fig. 1. WT, Tyk2-/- and Ifnar1-/- macrophages were treated with 100 ng/ml LPS for the 
times indicated or left untreated. The expression of (A) IL-17, (B) IL-17F and (C) TNF! 
mRNA was analysed by qRT-PCR. Ube2d2 was used for normalisation, and expression 
levels were calculated relative to untreated wildtype cells (WT 0 h). Data are depicted as 
mean ± SE derived from at least 3 independent experiments per time point; except for 0 h 
post treatment, mRNA expression levels in (A) and (B) were significantly different between 
Tyk2-/- and both other genotypes at all time points (p&0.01), mRNA expression levels in 
Ifnar1-/- differed from those in WT cells from 0 h up to 6 h post treatment (p&0.05) and no 
significant difference was obtained at later time points. (C) mRNA expression was not 
significantly different between the genotypes, except at 24 h post treatment between WT 
and both other genotypes (p&0.05). (D) IL-17 and (E) IL-17F accumulation was measured 
in cell culture supernatants with ELISA. Data are depicted as mean ± SE (D) from 4 and 
(E) from 3 independent experiments (comprising cells from 10 and 3 individual mice 
respectively; * p"0.05, ** p"0.01, *** p"0.001)  
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Fig. 2. WT and Tyk2-/- macrophages were treated with 100 ng/ml LPS or left untreated. At 
the times indicated, total cell lysates were prepared and subjected to Western blot 
analysis. Membranes were probed with Abs specific for (A) Tyr705-phosphorylated Stat3 
(pStat3) or Stat3 protein (Stat3), (B) Ser473-phosphorylated Akt (pAkt) or Akt protein 
(Akt), (C) Ser536-phosphorylated NF-%B p65 (pNF%B) or NF-%B p65 protein (NF%B). 
Protein loading was controlled by reprobing with anti-pan-ERK Ab (panERK). Data are 
representative for at least two independent experiments. 
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Fig. 3. Stat3fl/fl and Stat3Lyzs-/- macrophages were treated with 100 ng/ml LPS for the times 
indicated or left untreated. Expression of (A) IL-17, (B) IL-17F and (C) TNF! mRNA was 
analysed by qRT-PCR. Ube2d2 was used for normalisation and expression levels were 
calculated relative to untreated Stat3fl/fl cells (Stat3fl/fl 0 h). Data are depicted as mean ± 
SE from at least 3 independent experiments per time point; expression levels in (A) and 
(B) were significantly different between the genotypes at all time points (p&0.05 for 8 h 
post treatment, all other time points p&0.01); expression levels in (C) were only 
significantly different at 0 h (p&0.05). (D) IL-17 accumulation was measured in cell culture 
supernatants by ELISA. Data are depicted as mean ± SE from 3 independent experiments 
(comprising cells from 6 individual mice; ** p"0.01). 
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Fig. 4. (A) WT, Tyk2-/- and Ifnar1-/- or (B) Stat3fl/fl and Stat3Lyzs-/- or (C) WT and Rag2-/- 
mice were injected i.p. with LPS (1 mg per 20 g body weight) or left untreated. At the 
times indicated IL-17 mRNA expression in spleens was analysed by qRT-PCR. Ube2d2 
was used for normalisation and expression levels were calculated relative to the untreated 
WT (WT 0 h, Stat3fl/fl 0 h). Data are depicted as mean ± SE from at least 4 mice of 3 
independent experiments per time point; (** p&0.01, *** p&0.001). 
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Fig. 5. (A, B) WT or (C, D) WT and Tyk2-/- mice were injected i.p. with LPS (1 mg per 20 g 
body weight) or left untreated. Following 6 h LPS challenge spleen cells were separated 
via successive MACS, as indicated. (A, C) IL-17 or (B, D) IFN# mRNA expression in 
different spleen cell populations was analysed by qRT-PCR. Expression levels were 
calculated relative to the endogenous control (Ube2d2). Data are depicted as mean ± SE 
from 2 independent experiments. 
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Fig. 6. WT mice were injected i.p. with LPS (1mg per 20g body weight) or left untreated. 
Subsequently, mice were injected i.v. with 0.25 mg Brefeldin A and 6 h following challenge 
spleen cells were depleted of CD19+ cells by MACS and then FACSed. Dot plots show 
intracellular staining for IL-17 in (A) pDCs and (B) #$ T cells. Aggregates and dead cells 
were excluded based on FSC-H versus FSC-A plots. Among the resulting live cell singlet 
pDCs were determined as CD3–Siglec-H+ and #$ T cells as CD3+#$TCR+. Numbers in the 
gates indicate the percentage of IL-17+ cells in total (A) CD3–Siglec-H+ cells or (B) 
CD3+#$TCR+ cells. In the right panels of (A) and (B) the IL-17+ cells are depicted as mean 
± SD from 3 independent experiments (*** p"0.001).  
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Tyrosine Kinase 2 Controls IL-1b Production at the
Translational Level
Marta Radwan,*,†,1 Rita Stiefvater,*,1 Tom Grunert,*,‡ Omar Sharif,x,{
Ingrid Miller,† Martina Marchetti-Deschmann,‡ Gu¨nter Allmaier,‡ Manfred Gemeiner,†
Sylvia Knapp,x,{ Pavel Kovarik,‖ Mathias Mu¨ller,*,# and Birgit Strobl*
IL-1b is an important proinflammatory cytokine with a major role in several inflammatory diseases. Expression of IL-1b is tightly
regulated at the level of transcription, mRNA stability, and proteolytic processing. In this study, we report that IL-1b expression
in response to LPS is also regulated at the translational level. LPS-induced IL-1b protein levels in macrophages derived from
murine bone marrow are markedly increased in the absence of tyrosine kinase 2 (Tyk2). Increased IL-1b is found intra- and
extracellularly, irrespective of the efficiency of IL-1b processing. We show that the absence of Tyk2 results both in higher
translational rates and in enhanced association of IL-1b mRNA with polysomes. Induction and stability of IL-1b mRNA are
not affected by the lack of Tyk2. We show further that the Tyk2-dependent translational inhibition is mediated by autocrine/
paracrine type I IFN signaling and requires signal transducer and activator of transcription 1. Enhanced IL-1b production in
Tyk2- and IFN receptor 1-deficient macrophages is also observed following Listeria monocytogenes infection. Taken together, the
data describe a novel mechanism for the control of IL-1b synthesis. The Journal of Immunology, 2010, 185: 3544–3553.
T
yrosine kinase 2 (Tyk2) is a member of the Janus kinase
(Jak) family of nonreceptor tyrosine kinases (1). Jaks and
signal transducers and activators of transcription (Stats)
constitute the Jak/Stat signal transduction cascade that is used
by many cytokines and some growth factors (2). Binding of ligands
to their cognate receptors induces activation of Jaks, subsequent
auto- and/or transphosphorylation and phosphorylation of the sig-
nal transducing cytoplasmic receptor domains. These then serve as
docking sites for Stats, which upon phosphorylation by Jaks
translocate as hetero- or homodimers to the nucleus, bind to spe-
cific consensus elements in promoter regions and activate tran-
scription of target genes. Most prominently, Tyk2 is involved in
signal transduction of type I IFNs and IL-12 (3, 4). Accordingly,
mice lacking Tyk2 are more sensitive to most microbial infections
studied so far (3, 5–10). By contrast, Tyk2 deficiency results in
enhanced resistance against sterile inflammation and several in-
flammatory diseases (6, 11–15).
LPS is recognized by the TLR4 complex and leads to the acti-
vation of two main branches of signal transduction initiated at
different intracellular sites. The myeloid MyD88-dependent path-
way is essential for the activation of NF-kB and MAP kinases and
the subsequent induction of proinflammatory cytokines, whereas
the MyD88-independent pathway is required for the activation of
IFN regulatory factor 3 and the expression of type I IFNs (16, 17).
Type I IFNs bind to the receptor chains IFNAR1 and IFNAR2,
thereby activating Tyk2, Jak1, and subsequently, mainly Stat1/
Stat2 dimers. In combination with IFN regulatory factor 9 these
form IFN-stimulated gene factor 3, which activates the transcrip-
tion of a large number of IFN-responsive genes. Type I IFN re-
ceptor chains are widely expressed and thus autocrine/paracrine
actions of type I IFNs contribute substantially to the complex bi-
ological responses to LPS treatment in most, if not all, cell types.
The central involvement of IL-1b in awide range of inflammatory
and autoimmune diseases makes it an attractive target for thera-
peutic interventions (18–20). IL-1b expression is believed to be
regulated largely at the level of transcription and by its processing
and release (21, 22). In addition, regulation of IL-1b mRNA sta-
bility via AU-rich elements (ARE) has been reported (23). Pro–IL-
1b synthesis is induced by LPS through activation of the NF-kB and
MAPK pathways (24, 25), although NF-kB can also negatively
regulate IL-1b processing (26). Pro–IL-1b can be cleaved into the
biologically active cytokine by several proteases in the extracellular
space but caspase (casp) 1 is the main protease responsible for
cleavagewithin macrophages (27–29). Recently, casp-8–dependent
and casp-1–independent IL-1b maturation was reported in TLR2-
primed, LPS-stimulated peritoneal macrophages (30). Casp-1 itself
requires proteolytic processing for activation and this occurs within
an activated inflammasome. LPS is a strong inducer of pro–IL-1b
but a poor activator of the inflammasome and so only weakly
induces the release of mature IL-1b unless a second stimulus trig-
gers inflammasome activation (31–33).
*Institute of Animal Breeding and Genetics, †Institute of Chemistry and Biochemistry,
and #Biomodels Austria, University of Veterinary Medicine Vienna; ‡Institute of
Chemical Technologies and Analytics, Vienna University of Technology; xCenter
for Molecular Medicine, Austrian Academy of Sciences; {Division of Infectious Dis-
eases and Tropical Medicine, Department of Medicine I, Medical University Vienna;
and ‖Max F. Perutz Laboratories, Department of Microbiology, Immunobiology and
Genetics, University of Vienna, Vienna, Austria
1M.R. and R.S. contributed equally to this work.
Received for publication December 14, 2009. Accepted for publication July 8, 2010.
The work was supported by the Austrian Science Fund (SFB-F28 to M.M. and B.S.)
and the Austrian Federal Ministry for Science and Research (GZ.200.191/1-II/1a/
2008 to Biomodels Austria).
Address correspondence and reprint requests to Dr. Birgit Strobl, Institute of Animal
Breeding and Genetics, University of Veterinary Medicine Vienna, Veterina¨rplatz 1,
1210 Vienna. E-mail address: birgit.strobl@vetmeduni.ac.at
Abbreviations used in this paper: actD, actinomycin D; ARE, AU-rich elements; casp,
caspase; CHX, cycloheximide; CM, complete medium; 2D-DIGE, two-dimensional
fluorescence difference gel electrophoresis; I, IFNAR12/2; IFIT, IFN-induced protein
with tetratripeptide repeats; Jak, Janus kinase; MOI, multiplicity of infection; MS,
mass spectrometry; nd, not detectable; NFkBia, NF-kB inhibitor a; PAI2, plasminogen
activator inhibitor 2; RT-qPCR, reverse transcription-quantitative PCR; S, Stat12/2;
Stat, signal transducers and activators of transcription; T, Tyk22/2; TBP, TATA-box-
binding protein; TTP, tristetraprolin; Tyk2, tyrosine kinase 2; Ube2d2, ubiquitin-
conjugating enzyme E2 D2; W, WT; WT, wild-type.
Copyright 2010 by TheAmericanAssociation of Immunologists, Inc. 0022-1767/10/$16.00
www.jimmunol.org/cgi/doi/10.4049/jimmunol.0904000
 o
n
 Septem
ber 2, 2010 
w
w
w
.jimmunol.org
D
ow
nloaded from
 
By means of a two-dimensional fluorescence difference gel elec-
trophoresis (2D-DIGE) approach, we recently reported that lack of
Tyk2 results in strong alterations of the macrophage proteome both
before and after LPS stimulation (34). In the current study, we
identify IL-1b as a protein that is strongly enhanced in the absence
of Tyk2 upon LPS treatment in bone marrow-derived macro-
phages. Mechanistically, we show that Tyk2 limits IL-1b ex-
pression at the level of translation and provide evidence that this
Tyk2 function is dependent on canonical IFN-a/b signaling.
Materials and Methods
Animals and cells
Tyk2, IFNAR1, and Stat1 knockout mice have been described previously (3,
35, 36) and were backcrossed to C57BL/6 background for at least 10
generations. Bone marrow-derived macrophages were isolated and grown
in the presence of CSF-1 derived from L929 cells as described previously
(37). Cells were cultivated for 6 d in DMEM supplemented with 10% FCS,
15% L929 cell conditioned medium, 2 mM L-glutamine, 100 U/ml peni-
cillin, 100 mg/ml streptomycin, and 50 mM b-mercaptoethanol (complete
medium [CM]) prior to the experiments. All cell culture reagents were from
Invitrogen (Lofer, Austria). Mice were housed under specific pathogen-free
conditions according to FELASA guidelines. All animal experiments were
discussed and approved by the institutional ethics committee and con-
form with Austrian laws (68.205/0204-C/GT/2007 and 68.205/0233-II/10b/
2009).
Reagents and preparation of whole cell lysates
Cells were treated with 100 ng/ml LPS (Escherichia coli serotype 055:B5,
Sigma-Aldrich, St. Louis, MO) for the times indicated. IFN-b (Calbio-
chem, San Diego, CA) was used at the concentration of 100 U/ml. Acti-
nomycin D (actD; Sigma-Aldrich) and cycloheximide (CHX; Sigma-
Aldrich) were used at a concentration of 10 mg/ml. Whole cell lysates were
prepared as described previously (34). Listeria monocytogenes (EGD
strain) was kindly provided by Thomas Decker (Max F. Perutz Labora-
tories, University of Vienna, Vienna, Austria) and infections were per-
formed as described (38).
2D-DIGE and protein identification by mass spectrometry
DIGE labeling, 2-DE separation, evaluation/statistical analyses and protein
identification by MALDI-mass spectrometry (MS) and MS/MS have been
described previously (34). See Table I for detailed MS data.
Western blot analysis
Western blots were performed as described previously (34). The following
Abs were used: goat anti–IL-1b (R&D Systems, Minneapolis, MN), mouse
anti-panERK (BD Biosciences, San Diego, CA), donkey anti-goat IgG-
HRP (Santa Cruz Biotechnology, Santa Cruz, CA), sheep anti-mouse IgG-
HRP F(ab)92 fragment (GE Healthcare, Munich, Germany). Quantifica-
tions were performed using ImageJ software for Mac OS X (open source,
http://rsb.info.nih.gov/ij/index.html).
ATP treatment
Cells (23 106) were stimulated with LPS in 1.5 ml CM (see above) for 4 h,
washed once with PBS, 1.5 ml DMEM containing 3 mM, 5 mM ATP
(Sigma-Aldrich), or without supplements were added and cells were further
incubated for 30 min.
ELISA
Cell culture supernatants were collected and centrifuged at 14,000 3 g for
3 min and concentrations of IL-1b and TNF-a were determined using
ELISA (R&D Systems). Detection limits of ELISAs are 10 pg/ml and 25
pg/ml for IL-1b and TNF-a, respectively.
TCA precipitation of supernatants
Supernatants (900 ml) were mixed with 13.5 ml 10% (w/v) sodium deoxy-
cholate monohydrate (Sigma-Aldrich) (final concentration 0.15%) and
300 ml ice-cold 6.1 M TCA solution was added. Extracts were incubated 1 h
on ice to allow protein precipitation. Samples were centrifuged at 10,0003
g for 10 min at 4˚C. Supernatants were discarded, pellets were washed three
times with 1 ml ice-cold acetone and dissolved in 10 ml 0.2 M NaOH, di-
luted in 15 ml H2O and mixed with 25 ml 23 SDS-PAGE Laemmli sample
buffer, followed by boiling for 5 min. For Western blotting, 15 ml sample
was separated on a 15%T SDS-PAGE and probed with anti–IL-1b Abs.
Pulse/chase experiments and immunoprecipitation
Cells (33 106) were stimulated with LPS in CM (see above) for 2.5 h, then
washed once with PBS and incubated in LPS containing starving medium
(DMEM methionine/cysteine-free, 1% BSA, 2 mM L-glutamine, 15%
conditioned medium, 100 U/ml penicillin, 100 mg/ml streptomycin) for 30
min. Medium was replaced by 1.5–2 ml pulse medium (starving medium
supplemented with 70–100 mCi/ml [35S]methionine/cysteine [Met-35S-
label], Hartmann Analytic, Braunschweig, Germany) and cells were in-
cubated in the presence of LPS for the indicated pulse times. Cells were
washed once with PBS and incubated in chase medium (CM supplemented
with 15 mg/ml L-methionine and L-cysteine [Sigma-Aldrich]). IL-1b was
immunoprecipitated from 400 mg protein with hamster anti–IL-1b Ab (BD
Biosciences) using protein A-coupled Sepharose beads. Quantification of
signal intensities was performed with ImageJ software as described for
Western blots.
Polysome gradients
Sucrose gradient fractionation was performed as previously described (39)
with minor modifications. Cells (1.5 3 107) were lysed in 1 ml ice-cold
buffer (10 mM Tris-HCl pH 8, 150 mM NaCl, 1.5 mM MgCl2, 0.5%
[v/v] NP-40, 500 U RiboLock) and nuclei removed by centrifugation at
3,000 3 g, 4˚C for 2 min. The supernatant was supplemented with 20 mM
DTT, 150 mg/ml CHX, and 1 mM PMSF and centrifuged at 15,000 3 g,
4˚C for 5 min. Supernatants were layered onto 10 ml continuous 15–40%
(w/v) sucrose gradients (containing 10 mM Tris-HCl pH 7.5, 140 mM
NaCl, 1.5 mM MgCl2, 10 mM DTT, and 100 mg/ml CHX) and centrifuged
at 38,000 rpm, 4˚C for 2 h (Sorvall SW41 rotor; ThermoFisher Scientific,
Waltham, MA). Fractions (0.5 ml) were collected manually from top to
bottom. Proteins were digested with 100 mg proteinase K in the presence of
1% (w/v) SDS and 10 mM EDTA pH 8. RNA was extracted with
25:24:1 phenol-chloroform-isoamyl alcohol (Invitrogen), supplemented
with 1 ml glycogen (Sigma-Aldrich, ∼20 mg/ml), 225 mM sodium acetate
pH 5.2, and precipitated overnight with ethanol.
Reverse transcription-quantitative PCR
Reverse transcription-quantitative PCR (RT-qPCR) of total RNA was
performed as described previously (34). RT-qPCR of sucrose gradient-
fractionated mRNA: two fractions each were pooled and 4 ml RNA was
used for cDNA synthesis with iScript (Bio-Rad Laboratories, Vienna,
Austria). RT-qPCR was performed in duplicate on Eppendorf realplex4
(Eppendorf, Vienna, Austria). Expression levels of the target genes (TNF-
a, IL-1b, PAI2, NF-kB inhibitor a (NFkBia), and TATA box binding
protein [TBP]) were determined by RT-qPCR in each pooled fraction and
are given as percentages of the target mRNA in all fractions.
Primers and probes: the primers and probes for TNF-a (12), Ube2d2 (7),
and PAI2 (34) have been described previously. IL-1b was detected with
a TaqMan gene expression assay (assay ID Mm00434228_m1; Applied
Biosystems). TBP and NFkBia were detected with EVAGreen (Biotium,
Hayward, CA) using the following primers (59–39): TBP-fwd: 59-GAA-
TATAATCCCAAGCGATTTGC-39 (Tm = 58˚C); TBP-rev: 59-CTGGA-
TTGTTCTTCACTCTTGGCT-39 (Tm = 60˚C), amplicon length: 122 bp;
NFkBia-fwd: 59-TGGCCAGTGTAGCAGTCTTGAC-39 (Tm = 60˚C); and
NFkBia-rev: 59-CAGGTAGCCGTGAGTAGAGGCTAG-39 (Tm = 59˚C),
amplicon length: 117 bp.
Statistical analysis of RT-qPCR and ELISA data
RT-qPCR gene expression data were investigated for differences among
genotypes and time after challenge. Univariate regression was calculated
with the log of the transformed target to endogenous control gene expression
ratio as dependent variable. Linear contrasts were encoded such that for
each time point, Tyk22/2 were compared with wild-type (WT) cells.
Differences among experiments were taken into account. Analysis of
ELISA data with multiple measurements was performed using the log of
the data and as above. Data were analyzed with SPSS 17.0 for Mac OS-X.
For the analysis of ELISA data of single treatments/time points t tests
(Mann-Whitney) were used (Prism 5 software for Mac OS X; GraphPad
Software, La Jolla, CA).
In vivo LPS challenge
Age- (8–10 wk) and sex-matched mice were injected i.p. with 1 mg/20 g
body weight LPS. After 4 h, mice were anesthesized with ketamine-
xylazine and blood was collected retrobulbarly. For peritoneal lavages,
mice were sacrificed and peritonea flushed with 5 ml PBS.
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Results
Intracellular pro–IL-1b in response to LPS treatment is increased
in the absence of Tyk2 in bone marrow-derived macrophages
Using a 2D-DIGE and MALDI-MS approach, we recently reported
a regulatory role for Tyk2 in the expression of a number of proteins
before and after LPS treatment, whereby 21 of them were un-
ambiguously identified (34). In a subsequent analysis, we identi-
fied IL-1b in a spot that was differentially expressed between WT
and Tyk22/2 macrophages after LPS treatment (see Materials and
Methods and Table I for details on MS). IL-1b was found in
whole cell lysates in a spot with a Mr of ∼30 kDa and an iso-
electric point around 4.6. The peptides identified were common to
both mature (Mr of 17 kDa) and immature (Mr of 31 kDa) IL-1b
but based on the Mr the spot could be assigned to the latter (pro–
IL-1b). After 18 h, LPS treatment the levels of pro–IL-1b were
found to be higher in Tyk22/2 cells than in WT cells (Fig. 1A,
1B). Spot volume ratios as determined by 2D-DIGE increased
in WT cells upon 18 h LPS treatment by ∼3-fold, whereas a sig-
nificantly stronger increase (∼14-fold) was found in the absence of
Tyk2 (Fig. 1B). Enhanced levels of pro–IL-1b in whole cell lysates
from Tyk22/2 macrophages were confirmed by Western blot time
course experiments (Fig. 1C) and were detected from around 2 h
after LPS stimulation onward. As reported previously (40–42),
mature IL-1b was hardly detectable in cell extracts after LPS
treatment (Fig. 1C).
IL-1b mRNA induction and stability are similar in WT and
Tyk22/2 macrophages
Induction of IL-1b gene expression in response to LPS treatment
in macrophages occurs via the MyD88-dependent pathway (43,
44), which is not believed to depend on Tyk2 (12, 34). Consistent
with this notion, we found no significant differences in IL-1b
mRNA levels between WT and Tyk22/2 macrophages in time-
course experiments (Fig. 2A). IL-1b mRNA was induced rapidly
within the first hour of LPS treatment in WT and Tyk22/2 cells,
reached its maximal level expression around 12 h after LPS
treatment and remained high for up to 20 h. As expected, TNF-a
mRNA was induced to a similar extent in WT and Tyk22/2
macrophages (Fig. 2B). To determine also the effects of Tyk2 on
mRNA stability, cells were treated with LPS for 4 h and sub-
sequently incubated with the transcriptional inhibitor act D for the
times indicated. mRNA levels of IL-1b and proinflammatory re-
sponse genes as controls were determined at different times after
treatment using RT-qPCR. IL-1b mRNA was stable (Fig. 2C) as
described previously in the context of LPS responses (45) and no
Table I. Detailed MS data for the unambiguous identification of IL-1b (Swissprot accession no. P10749)
Peptide mass
fingerprint
Probability based MOWSE score (significant score . 55, p , 0.05) 47
Sequence coverage 8%
Matched/unmatched peptides 3/1
Sequencing No. of peptides used for protein ID 3
Probability based MOWSE score (significant ion score . 30, p , 0.05) 130
Monoisotopic values of precursor ion(s) [M+H]+ m/z (selected) 716.38
916.48
1263.74
Peptide sequences obtained QLHYR
LRDEQQK
SLVLSDPYELK
FIGURE 1. Pro–IL-1b protein expression is elevated in the absence of Tyk2. Macrophages were treated with LPS for the indicated times and whole cell
lysates were subjected to 2D-DIGE (A, B) or Western blot analysis (C). A, Selected regions from Cy3 and Cy5 images converted to gray scale showing pro–
IL-1b spot positions (indicated by arrows). B, Protein expression levels are given as fold ratios relative to untreated WT cells. Mean values 6 SD of three
biological replicates are shown. ppp # 0.01. C, Five microgram protein per lane were separated by 14%T SDS-PAGE and subjected to Western blot
analysis. Membranes were probed with an anti–IL-1b Ab; protein loading was controlled by reprobing with an anti-panERK Ab.
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difference was observed between WT and Tyk22/2 cells. Con-
sistent with other reports (45), mRNA of TNF-a and NFkBia
decayed rapidly. No differences between WT and Tyk22/2 cells
were observed for TNF-a and NFkBia mRNA decay (Fig. 2D,
2E). Ubiquitin-conjugating enzyme E2 D2 (Ube2d2) mRNA,
which was used as a endogenous control for most of the RT-qPCR
analyses, was very stable and as expected its level was not affected
by the absence of Tyk2 (Fig. 2F).
Intra- and extracellular levels of IL-1b are enhanced in the
absence of Tyk2
IL-1b processing and release is tightly regulated. LPS stimulation
alone massively induces pro–IL-1b production but processing and
externalization occurs very inefficiently (31, 32, 46). Thus, IL-1b
remains largely intracellular as unprocessed pro–IL-1b and only
low levels of mature IL-1b can be detected in the extracellular
space. Nevertheless, and to test whether the increased intracellular
pro–IL-1b level in Tyk22/2 cells is caused by reduced IL-1b pro-
cessing and/or release, we determined the amount of extracellular
IL-1b with ELISA. As shown in Fig. 3A, the amounts of IL-1b
protein detected in the supernatants were low in WT cells with
around 50–100 pg/ml at 24 h after LPS stimulation. The level
of IL-1b was increased by ∼4- to 5-fold in Tyk22/2 macrophage
supernatants. Again consistent with previous studies (12), secreted
levels of TNF-a were similar in WT and Tyk22/2 cells (Fig. 3B).
We next asked whether increased IL-1b production in Tyk22/2
cells is also observed under conditions that promote maturation of
IL-1b (32). Macrophages were treated for 4 h with LPS, followed
by 30 min stimulation with the receptor agonist ATP (3 or 5 mM).
In contrast to the 8 h time point (Fig. 3A), treatment with LPS
alone for 4 h resulted in barely detectable levels of IL-1b and
a slight, but not significant increase in Tyk22/2 cells (Fig. 4A). As
expected, extracellular levels of IL-1b in WT cells were dramat-
ically higher (∼1600 pg/ml) after addition of ATP (Fig. 4A). Im-
portantly, significantly enhanced IL-1b levels were detected in
Tyk22/2 macrophages in the presence of 3 mM and 5 mM ATP
(Fig. 4A).
As the ELISA might also detect unprocessed IL-1b, we used
Western blot analysis to verify these results. Under our experi-
mental conditions, IL-1b was not detectable in supernatants
of cells treated with LPS alone (data not shown), whereas pro–IL-
1b and mature IL-1b could be detected in supernatants of
WT cells after treatment with 5 mM ATP (Fig. 4B). Strongly
enhanced IL-1b levels were detected in the absence of Tyk2 and
mature IL-1b was readily detectable at concentrations of 3 mM
and 5 mM ATP, respectively. Importantly, mature 17 kDa IL-1b
FIGURE 2. IL-1b mRNA expression and stability is unaltered in Tyk22/2 cells. Macrophages were treated with LPS for the times indicated and total
RNA was subjected to RT-qPCR for IL-1b (A) or TNF-a (B). mRNA expression levels were calculated relative to untreated WT cells, with Ube2d2
as endogenous control. Mean values 6 SE from at least three independent experiments are shown. No significant differences were found. Macrophages
were treated with LPS for 4 h and act D was added for the indicated times (C–F). Total RNAwas isolated and subjected to RT-qPCR analysis for IL-1b (C),
TNF-a (D), NFkBia (E), and Ube2d2 (F). Mean values 6 SD from three replicates derived from two independent experiments are depicted.
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was also increased in supernatants of Tyk2-deficient cells (Fig.
4B). Intracellular, mature IL-1b was not detectable in WT cells
treated with LPS/ATP (Fig. 4C). In contrast, mature IL-1b was
detectable even intracellularly in Tyk22/2 cells after treatment
with LPS and 5 mM ATP (Fig. 4C).
In summary, the data show that both intra- and extracellular
levels of pro–IL-1b and mature IL-1b are increased in the absence
of Tyk2 as compared with WT cells, independently of the pres-
ence of a trigger that promotes IL-1b processing.
Limitation of IL-1b expression depends on the presence of
IFNAR1 and Stat1
In the context of macrophage LPS responses, Tyk2 is mainly as-
sociated with IFN-a/b signaling. Maximum levels of basal and/
or induced expression of at least some genes that depend on
functional IFN-a/b responses are only observed in the presence of
Tyk2 (3, 7, 12). We thus asked whether the inhibitory role of Tyk2
in IL-1b expression may be extended to other signaling molecules
of the type I IFN pathway. To this end, cells lacking IFNAR1 or
Stat1 were treated with LPS for 4 or 18 h, with or without additional
incubation with ATP. IL-1b expression was analyzed in super-
natants by Western blotting (Fig. 5A). IL-1b levels were enhanced
to a similar extent in IFNAR12/2, Tyk22/2, and Stat12/2 cells at
both times of treatment and, additionally, levels of processed IL-1b
were also clearly higher than inWT cells. Similarly, enhanced pro–
IL-1b and low levels of mature IL-1bwere observed intracellularly
in the absence of IFNAR1, Tyk2, or Stat1 after LPS treatment,
independent of the presence of ATP (Fig. 5B). We note that our data
on Stat12/2 cells contradict a previous report showing reduced
extracellular levels of IL-1b protein upon LPS treatment in the
absence of Stat1 in thioglycollate-elicited peritoneal macro-
phages (47). It seems likely that this discrepancy can be explained
by differences in the macrophage populations used, namely, resting
versus inflammatory.
To test whether similar effects occur in response to infection with
a pathogen that readily activates the inflammasome (48), we infected
macrophages with Listeria monocytogenes and monitored IL-b
levels. IL-1b concentrations in supernatants of infected cells were in
the range of those found in LPS/ATP-treated cells. Again, increased
IL-1b was found in whole cell extracts (Fig. 5C) and cell super-
natants (Fig. 5D) in the absence of either Tyk2 or IFNAR1. IL-1b
secretion occurred more efficiently in cells infected with L. mono-
cytogenes than after LPS/ATP treatment, as we could not detect any
mature IL-1b in whole cell extracts (data not shown). Extracellular
IL-1b amounts as detected by ELISA were increased around 5- to
10-fold in both Tyk2- and IFNAR1-deficient as compared with WT
cells (Fig. 5D). In contrast, the level of TNF-a was similar in WT
and Tyk22/2 macrophages and interestingly decreased in IFNAR1-
deficient cells (Fig. 5E).
Based on the conclusion that LPS-induced, autocrine/paracrine
IFN-a/b signaling can inhibit IL-1b protein expression, we tested
whether addition of exogenous IFN-b can decrease IL-1b pro-
duction. For that purpose, WT and Tyk22/2 cells were pretreated
with IFN-b for 1 h, or left untreated, and then subsequently treated
with LPS for 24 h, or left untreated. A clear decrease in IL-1b
protein expression could be observed in WT and Tyk22/2 cells
that were pre- or cotreated with IFN-b, whereby pretreatment had
a more pronounced effect (Fig. 6A, data not shown). These data
confirm previous observations in human whole blood cells (49)
where type I IFN treatment was found to decrease IL-1b protein
production. IFN-b pretreatment decreased intracellular pro–IL-1b
levels by ∼10-fold in WT cells as determined by quantification of
Western blot data (Fig. 6B). As expected, and in accordance with
FIGURE 3. Extracellular protein levels of IL-1b are elevated in
Tyk22/2 cells. Macrophages were treated with LPS for the times indicated
and cell culture supernatants collected. Extracellular protein concen-
trations of IL-1b (A) and TNF-a (B) were measured by ELISA. Mean
values 6 SD from three independent experiments are shown; ppp # 0.01.
nd, not detectable.
FIGURE 4. Pro- and mature IL-1b, and intra- and extracellular protein
levels of IL-1b are higher in the absence of Tyk2, independent of the
presence of ATP. Macrophages were treated with LPS for 4 h with or
without subsequent addition of ATP at the concentrations indicated for 30
min. A, Extracellular IL-1b concentrations were measured by ELISA.Mean
values6 SD from three independent experiments are shown, ppp# 0.01. B,
Proteins were precipitated from supernatants and 15 ml per lane were
subjected toWestern blot analysis by 15%T SDS-PAGE.C, Five microgram
protein from whole cell lysates per lane were separated by 15%T SDS-
PAGE. B and C, Membranes were probed with an anti–IL-1b Ab. Data are
representative for three independent experiments. T, Tyk22/2; W, WT.
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the amplifying role of Tyk2 in IFN-a/b signaling (3, 4), inhibition
by IFN-b still occurred but was less pronounced (∼2-fold)
in Tyk22/2 cells (Fig. 6B). IL-1b levels in supernatants from
WT cells were decreased to below the detection limit of the
ELISA (Fig. 6C) and by around 5-fold in Tyk22/2 cells. In WT
and Tyk22/2 cells we were unable to observe any effect on TNF-a
levels of pretreatment with IFN-b for 1 h (Fig. 6D).
The increased amount of IL-1b in Tyk2
2/2
cells is caused by
enhanced protein synthesis
We next determined whether IL-1b protein stability is influenced
by the absence of Tyk2. Macrophages were stimulated with LPS
for 4 h, the translational inhibitor CHX was added and IL-1b
protein expression monitored over time. As described previously,
IL-1b protein levels were increased in Tyk22/2 as compared with
WT cells at 4 h of LPS stimulation. IL-1b protein levels declined
after 6 h and 12 h addition of CHX in both WT and Tyk22/2 cells
(Fig. 7A) and no significant differences could be observed.
Because the protein synthesis inhibitor CHX might introduce
artifacts, for example, by blocking the expression of a labile pro-
tease, we confirmed the results by metabolic labeling with
[35S]methionine/cysteine in pulse-chase experiments. Cells
were treated with LPS for 4 h, labeled with [35S]methionine/
cysteine (pulse), washed and further incubated in the presence
of excess cold methionine/cysteine for various times (chase).
We found clear differences in IL-1b synthesis between WT and
Tyk22/2 cells during the 1 h and 2 h pulse periods (Fig. 7B, 7C).
The observed half-life of IL-1b in WT cells was similar to that
previously described (50) and not greatly different between WT
and Tyk2-deficient cells (Fig. 7B, 7D). The data thus indicate
that Tyk2 deficiency results in enhanced translation of IL-1b
rather than in increased protein stability.
Association of IL-1b mRNA with polysomes is enhanced in the
absence of Tyk2
To test directly whether Tyk2 influences the translation of IL-1b
mRNA, we fractionated cytoplasmic RNA from LPS-treated WT
and Tyk22/2 macrophages via sucrose gradients (Fig. 8A) and
compared mRNA distributions among the different fractions (Fig.
8B–E). After 4 h LPS stimulation of WT cells, IL-1b mRNA was
found in the ribosome-free fractions as well as in association with
polysomes (Fig. 8B). In contrast, IL-1b mRNA was significantly
enriched in the polysomal fractions in Tyk22/2 cells (p = 0.019).
We also observed differences in the IL-1b polysome profiles after
14 h of LPS treatment, although IL-1b mRNAs were generally
shifted toward the ribosome-free mRNA fractions (data not
shown). As previously reported (51, 52), TNF-a mRNAwas found
in monosomal and polysomal fractions in WT cells treated with
LPS (Fig. 8C). In accordance with the unchanged expression of
TNF-a protein, TNF-a mRNA showed similar polysome profiles
in WT and Tyk2-deficient cells (Fig. 8C). Furthermore, we ob-
served no difference in mRNA profiles of the two housekeeping
FIGURE 5. Effect of IFNAR1 and Stat1 deficiency on IL-1b production induced by LPS and Listeria monocytogenes infection.A and B, Macrophages were
treated with LPS for the times indicated with or without subsequent addition of ATP for 30min.C–E, Macrophages were infected with L. monocytogenes at an
MOI of 10 for the indicated times. A, Proteins were precipitated from supernatants and 15 ml per lane separated by 15%T SDS-PAGE. B, Five microgram or
(C) 10 mg protein from whole cell lysates per lane were separated by 15%T SDS-PAGE. A–C, Membranes were probed with an anti–IL-1b Ab. B and C,
Protein loading of whole cell extracts was controlled by reprobing membranes with an anti-panERK Ab. D and E, Extracellular IL-1b and TNF-a con-
centrations were measured by ELISA. Mean values 6 SD from three independent experiments are depicted. nd, not detectable; pp # 0.05, ppp # 0.01 as
compared withWT cells.Western blot results (A–C) are representative of at least two independent experiments. I, IFNAR12/2; MOI, multiplicity of infection;
S, Stat12/2; T, Tyk22/2; W, WT.
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genes, TBP and Ube2d2 (Fig. 8D, data not shown). To assess the
specificity of the translational effects, we monitored plasminogen
activator inhibitor 2 (PAI2/serpinb2) mRNA. We had previously
identified PAI2 as an LPS-inducible protein whose expression is
regulated posttranscriptionally by Tyk2-dependent mechanisms
(34). In support of and extending these results, we show that
significantly more PAI2 mRNA associates with polysomes in the
absence of Tyk2 (Fig. 8E, p = 0.008).
Local IL-1b levels are increased in the absence of Tyk2 after
LPS challenge in vivo
Previous studies have not reported differences in the in vivo IL-1b
levels in Tyk2-deficient mice treated with LPS (12). Because this
analysis was limited to systemic cytokine levels and to very early
time points after LPS injection, we examined in more detail
whether Tyk2 might have an inhibitory role on IL-1b production
in vivo. WT and Tyk22/2 mice were injected i.p. with LPS and IL-
1b was measured in peritoneal lavages and in sera. As shown in
Fig. 9A, IL-1b levels were increased ∼2-fold in the peritonea
of Tyk22/2 as compared with WT mice at 4 h post injection. Al-
though the increase in IL-1b was less pronounced than in macro-
phages in vitro, the result supports our model for an inhibitory role
of Tyk2 on IL-1b production. In contrast, serum levels of IL-1b
were slightly lower in Tyk22/2 mice at 4 h after challenge (Fig.
9B), suggesting differences in the regulation of local versus sys-
temic IL-1b. Alternatively, kinetic differences in the regulatory
pathways might lie behind the apparent differential effect of Tyk2
deficiency on IL-1b levels in the peritoneal cavity and systemically.
Discussion
We show that IL-1b protein expression in response to LPS is
strongly increased in the absence of Tyk2 and that the effect does
not stem from changes to IL-1b mRNA induction or stability
(Figs. 1A–C, 2A, 2C). The lack of inhibition of IL-1b mRNA
induction is in accordance with previous observations that acti-
vation of the NF-kB and MAPK pathways is normal in Tyk2-
FIGURE 6. Effect of exogenous IFN-b on IL-1b
protein levels. Macrophages were pretreated with IFN-
b for 1 h or left untreated and subsequently treated
with LPS or left untreated for 24 h. A, 5 mg protein
from whole cell lysates per lane were separated by
15%T SDS-PAGE. Membranes were probed with an
anti–IL-1b Ab and protein loading controlled by
reprobing membranes with an anti-panERK Ab. W,
WT; T, Tyk22/2. B, Mean values of pro–IL-1b signal
intensities from three independent experiments. C, IL-
1b and (D) TNF-a were measured in cell supernatants
by ELISA, mean values 6 SD from three independent
experiments are depicted.
FIGURE 7. Pro–IL-1b protein sta-
bility and synthesis in the presence
or absence of Tyk2. A, Macrophages
were treatedwithLPS for 4h, 10mg/ml
CHXwas added and cells were further
cultivated for the times indicated. Five
microgram protein from whole cell
lysates per lane were separated by
15%T SDS-PAGE. Membranes were
probed with an anti–IL-1b Ab, protein
loading was controlled by reprobing
with an anti-panERK Ab. B, Macro-
phages were pulse labeled with [35S]
methionine/cysteine and chased for the
indicated times. IL-1b was immuno-
precipitated from 400 mg whole cell
extracts and detected by autoradiogra-
phy.C andD, Quantifications of signal
intensities from B for (C) the three
different pulse-periods and (D) 1 h
pulse and the different chase periods.
Results are representative of two in-
dependent experiments. T, Tyk22/2;
W, WT.
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deficient macrophages (12, 34). We can eliminate the possibility
that defects in processing/release of IL-1b lie behind the enhanced
intracellular IL-1b levels, as IL-1b was increased in cell super-
natants (Fig. 3A). Under conditions that efficiently activate the
inflammasome and pro–IL-1b conversion (i.e., ATP treatment),
the levels of mature IL-1b in Tyk2-deficient macrophages are
enhanced (Figs. 4B, 4C, 5A, 5B). Similarly, intra- and extracellular
IL-1b levels were enhanced in Tyk22/2 macrophages infected
with L. monocytogenes (Fig. 5C, 5D). By pulse–chase experiments
and using the translational inhibitor CHX, we show that IL-1b
protein stability does not depend on the presence of Tyk2 (Fig. 7A,
7B, 7D). In contrast, IL-1b protein synthesis within a given pulse-
period is enhanced in Tyk22/2 cells (Fig. 7B, 7C), suggesting an
increased rate of translation. In line with this finding, IL-1b
mRNA association with polysomes is enhanced in the absence of
Tyk2 (Fig. 8B). The association of PAI2 mRNA with polysomes
also increases (Fig. 8E), providing a mechanistic explanation for
the posttranscriptional upregulation of PAI2 in Tyk22/2 cells that
has been reported previously (34). Importantly, TNF-a mRNA
shows similar polysome profiles in WT and Tyk22/2 cells (Fig.
8C) and similar levels of TNF-a protein are found in cell super-
natants (Fig. 3B). Hence, the translational inhibition mediated by
Tyk2 is specific, at least to some degree.
An increase in IL-1b protein level is observed in IFNAR12/2
and Stat12/2 macrophages, both intra- and extracellularly and
independent of ATP treatment (Fig. 5A, 5B). Furthermore, IFN-b
pretreatment inhibits LPS-induced IL-1b protein expression in
WT cells, and to a lesser extent in Tyk22/2 cells, without affecting
TNF-a levels (Fig. 6). This argues that autocrine/paracrine ca-
nonical IFN-a/b signaling is the signaling cascade involved, al-
though we have as yet no direct evidence for an effect of IFNAR1
and Stat1 on translational control of IL-1b.
IFN-mediated translational inhibition has been known for a long
time (53–55) and the underlying mechanisms have been exten-
sively studied. Activated IFN-inducible RNA-dependent protein
kinase phosphorylates the a subunit of eukaryotic translation ini-
tiation factor 2A, which results in the inhibition of viral protein
synthesis (56, 57). Interestingly, Tyk2 has been reported to activate
protein kinase R directly (58). Two other closely related and
IFN-inducible proteins, ISG54 (IFIT2) and ISG56 (IFIT1), can
negatively regulate translation (59–62) by inhibiting the formation
of the translation initiation complex, although they target different
steps (63). Interestingly, the level of stimulation of both IFIT1 and
IFIT3 (another member of the IFIT protein family) in response to
LPS is reduced in the absence of Tyk2 (34). Little is known about
the specificity of these pathways and it is difficult to explain the
effects on the translation of IL-1b and PAI2 but not TNF-a and
NFkBia mRNAs (Fig. 8). It is noteworthy that IL-1b and PAI2
mRNAs are both fairly stable, whereas TNF-a and NFkBiamRNAs
FIGURE 8. Polysome profile of IL-
1b, TNF-a, TBP, and PAI2 mRNAs.
Macrophageswere treatedwith LPS for
4 h and cytoplasmic extracts separated
in a continuous 15–40% sucrose gra-
dient by ultracentrifugation. Fractions
were manually collected from top to
bottom and deproteinized andRNAwas
extracted. A, Polysomal fractions were
separated on 0.8% agarose gels. Rep-
resentative results are shown forWTand
Tyk22/2 macrophages. B–E, Two frac-
tions eachwere pooled andmRNA levels
determined by RT-qPCR. Amounts of
the mRNA per fraction for IL-1b (B),
TNF-a (C), TBP (D), and PAI2 (E) are
given as percentage of mRNA present
in all fractions of each genotype. Mean
values6SDof three independent experi-
ments are shown. pp# 0.05; ppp# 0.01.
FIGURE 9. Effect of Tyk2 deficiency on IL-1b production in vivo. WT
and Tyk22/2 mice were injected with LPS (1 mg/20 g body weight) i.p.
IL-1b was measured 4 h after challenge in (A) peritoneal lavages and (B)
sera by ELISA. Mean values 6 SE for (A) 16 or (B) 15 mice from three
independent experiments are depicted. pp # 0.05.
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decay more rapidly [Fig. 2C–F, data not shown, and (45)]. It may be
interesting to analyze whether stable mRNAs are more subject to
translational regulation than unstable ones. High-throughput pol-
ysomal profiling experiments or ribosome sequencing approaches
would be required to address these speculations. A recent report
describes positive regulatory effects of IFNs on translation that
appear to be specific to genes stimulated by IFN (64).
A large number of cytokines are known to be regulated at the
posttranscriptional level (65). Regulation occurs via AREs in the
39-UTRs of the mRNAs and several different ARE-binding pro-
teins regulate mRNA stability positively or negatively and can also
affect translational efficiency. Early studies reported that IL-1b can
be regulated at the translational level under certain conditions (66–
68) but the mechanism and stimuli involved remain largely un-
known. More recently (52), steroid receptor coactivator-3 has been
shown to be required for the translational repression of TNF-a and
IL-1b in response to LPS in peritoneal macrophages, although the
underlying mechanism was only described for TNF-a. IFN-a/b,
and p38 MAPK synergistically induce expression of the ARE-BP
tristetraprolin (TTP) (69). TTP destabilizes several cytokine and
chemokine mRNAs, including IL-1b (70–72), and can also in-
fluence translation (73). Surprisingly, we find that TTP expression
is increased in response to LPS in the absence of Tyk2 (data not
shown), arguing against an involvement of TTP in the translational
regulation of IL-1b. However, TTP activity is known to be regu-
lated by phosphorylation (74) and it is possible that Tyk2 affects the
phosphorylation status of TTP.
Tyk22/2 mice are highly resistant to high-dose LPS-mediated
endotoxin shock, but serum levels of TNF-a and IL-1b have been
reported to be normal in these mice at early stages (1.5 h) after
LPS injection (12). In support of our in vitro data, we find in-
creased IL-1b levels in the peritoneal lavages from Tyk22/2 mice
after LPS injection (Fig. 9A). Interestingly, and extending previous
results (12), systemic IL-1b levels are slightly but significantly
lower in Tyk22/2 mice 4 h after LPS challenge (Fig. 9B). Our data
thus point to differences in the regulation of local versus systemic
IL-1b production. The underlying mechanisms are unclear but it is
possible that IL-1b in the peritoneal cavity and the blood may
stem largely from different sources and that positive/negative
regulatory pathways might be differentially active at different
times, in different tissues, cell types, and/or in response to acti-
vation by different stimuli. Consistent with this hypothesis, we see
decreased IL-1b production in the lungs of Tyk22/2 mice after
intranasal LPS administration (data not shown). We conclude that
the inhibitory role of Tyk2 is relevant in vivo, although its specific
contribution to the complex regulation of IL-1b is highly de-
pendent on the cellular context and, presumably, the specific mode
and state of activation.
IL-1b–deficient mice respond to systemic LPS challenge sim-
ilar to WT mice (75), so it is unlikely that the enhanced local IL-
1b expression in the absence of Tyk2 contributes to the LPS-
resistant phenotype. Nevertheless, the suppressive role of Tyk2
on IL-1b expression that we describe raises the possibility that
Tyk2 might have protective functions during IL-1b–driven dis-
eases. In mice, IL-1b is involved in the pathogenesis of several
autoimmune and inflammatory diseases, for example, turpentine-
induced local inflammation, contact hypersensitivity, and collagen-
induced arthritis (76). Tyk2 seems not to act protectively during
autoimmune and inflammatory diseases but may actually exacer-
bate the symptoms. An exception is contact hypersensitivity, where
Tyk2 exerts protective functions: Tyk22/2 mice show increased
sensitivity (77). Enhanced IL-1b expression in the absence of Tyk2
would be consistent with these findings. However, it is important
to bear in mind that other functions of Tyk2, in particular in
IL-12 signaling/IFN-g production, might override the effects of
Tyk2 on IL-1b expression.
In summary, we report a hitherto undescribed negative regula-
tory function for Tyk2 on IL-1b expression in response to LPS. We
show that this occurs at the level of translation and most probably
depends on canonical type I IFN signaling.
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Research articleTranscriptome analysis reveals a major impact of 
JAK protein tyrosine kinase 2 (Tyk2) on the 
expression of interferon-responsive and metabolic 
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Abstract
Background: Tyrosine kinase 2 (Tyk2), a central component of Janus kinase/signal transducer and activator of 
transcription (JAK/STAT) signaling, has major effects on innate immunity and inflammation. Mice lacking Tyk2 are 
resistant to endotoxin shock induced by lipopolysaccharide (LPS), and Tyk2 deficient macrophages fail to efficiently 
induce interferon α/β after LPS treatment. However, how Tyk2 globally regulates transcription of downstream target 
genes remains unknown. Here we examine the regulatory role of Tyk2 in basal and inflammatory transcription by 
comparing gene expression profiles of peritoneal macrophages from Tyk2 mutant and wildtype control mice that were 
either kept untreated or exposed to LPS for six hours.
Results: Untreated Tyk2-deficient macrophages exhibited reduced expression of immune response genes relative to 
wildtype, in particular those that contain interferon response elements (IRF/ISRE), whereas metabolic genes showed 
higher expression. Upon LPS challenge, IFN-inducible genes (including those with an IRF/ISRE transcription factor 
binding-site) were strongly upregulated in both Tyk2 mutant and wildtype cells and reached similar expression levels. 
In contrast, metabolic gene expression was strongly decreased in wildtype cells upon LPS treatment, while in Tyk2 
mutant cells the expression of these genes remained relatively unchanged, which exaggerated differences already 
present at the basal level. We also identified several 5'UR transcription factor binding-sites and 3'UTR regulatory 
elements that were differentially induced between Tyk2 deficient and wildtype macrophages and that have not 
previously been implicated in immunity.
Conclusions: Although Tyk2 is essential for the full LPS response, its function is mainly required for baseline expression 
but not LPS-induced upregulation of IFN-inducible genes. Moreover, Tyk2 function is critical for the downregulation of 
metabolic genes upon immune challenge, in particular genes involved in lipid metabolism. Together, our findings 
suggest an important regulatory role for Tyk2 in modulating the relationship between immunity and metabolism.
Background
The first crucial step in successfully fighting infections is
the sensing of microbial products by innate immune cells,
e.g. macrophages and dendritic cells [1]. Toll-like recep-
tors (TLRs) sense microbial products and initiate a cas-
cade of signaling events to alert the immune defense.
Members of the TLR family recognize a range of patho-
gen-associated molecular patterns produced by bacteria,
protozoa, fungi, or viruses [2,3]. One of the best studied
examples for a pathogen associated pattern is bacterial
lipopolysaccharide (LPS). Binding of LPS to the TLR4
complex of the host activates two signaling cascades via
different adaptor proteins leading to the activation of two
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main transcription factors: NFκB, a key transcription fac-
tor regulating pro-inflammatory genes, and interferon
(IFN) regulatory factor 3 (IRF3), which induces IRF3-
responsive genes, most prominently IFNβ. IFNβ and
other cytokines subsequently act in an autocrine/para-
crine manner to induce the expression of immune
responsive genes [4,5].
A major component of IFNα/β signaling is Tyrosine
kinase 2 (Tyk2), a member of the Janus kinase (JAK) fam-
ily [6]. Activated JAKs phosphorylate members of the sig-
nal transducer and activator of transcription (STAT)
family, which mediate signals from a large number of
cytokines and growth factors [7,8]. Activation of JAK1
and Tyk2 by IFNα/β stimulation leads to a series of phos-
phorylation events, causing the formation of IFN stimu-
lated gene factor 3 (ISGF3) complexes that consist of
STAT1, STAT2 and IFN regulatory factor 9 (IRF9). Sub-
sequently, ISGF3 translocates to the nucleus and binds to
a specific transcription factor binding-site (TFBS), the
IFN stimulated response element (IRF/ISRE), which in
turn activates transcription of several hundred IFN-
responsive genes. To a lesser extent, these signaling
events also lead to the formation of STAT1 and STAT3
homo- and heterodimers that bind another TFBS, the
IFNγ activated sequence (GAS TFBS) [9].
In mice, Tyk2 is only partially required for IFNα/β sig-
naling, where it mainly serves to amplify the immune
response [10,11]. We and others have previously shown a
surprisingly low susceptibility of Tyk2 knockout mice to
LPS-induced endotoxin shock, despite normal produc-
tion of proinflammatory cytokines (the interleukins IL6,
IL1B) and tumor necrosis factor α (TNFα) [12,13]. In
vitro, Tyk2 mutant peritoneal macrophages fail to effi-
ciently induce IFNα/β and nitric oxide (NO) production
upon LPS treatment. In addition, Tyk2 deficiency influ-
ences the basal level of several IFN-responsive genes
[10,12]. However, despite the importance of Tyk2 in
mediating immune and inflammatory responses, how
this JAK regulates global transcription of downstream
target genes remains largely unknown.
Here we compare the genome-wide expression profiles
of Tyk2 mutant and wildtype mouse peritoneal mac-
rophages with and without activation by LPS using
microarrays. In particular, we focus on IFN-responsive
genes and their putative regulators and use bioinformatic
analysis to examine how the observed changes in gene
expression relate to gene ontology categories and cis-reg-
ulatory elements (i.e., 5'UR TFBSs and 3'UTR elements)
[14]. We find that Tyk2 is essential for mediating the full
LPS response and for baseline expression of IFN-induc-
ible genes, but not for the LPS-induced upregulation of
IFN-responsive genes. Moreover, we show that LPS chal-
lenge suppresses the expression of genes involved in
metabolism and we establish a critical role for Tyk2 func-
tion in this downregulation.
Results
Effects of Tyk2 and LPS on gene expression
To determine the effects of Tyk2 and LPS on gene expres-
sion we used CodeLink Mouse Whole Genome Arrays on
mRNA isolated from Wt (C57BL/6) and Tyk2-/- (on a
C57BL/6 background) macrophages, either stimulated
with LPS for six hours or kept untreated. After filtering
and quality control, we retained 7546 genes for statistical
and bioinformatic analysis (see Methods).
At the basal level, in the absence of LPS stimulation, we
found that 428 (6%) of 7546 genes analyzed were differen-
tially expressed between Wt and Tyk2-/- macrophages
(effect of genotype, Figure 1A; full dataset available at
Gene Expression Omnibus http://www.ncbi.nlm.nih.gov/
geo/, GEO accession number GSE19733). Among the
genes with the largest expression differences between
genotypes, many are known to be involved in immune
function. The majority of these genes was downregulated
Figure 1 Effects of Tyk2 and LPS on overall gene expression. Ef-
fects of (A) Tyk2 genotype (Wt minus Tyk2-/-), (B) LPS treatment (6 
hours of LPS minus control), and (C) genotype by treatment interaction 
(difference in LPS induction between Wt and Tyk2-/-) on expression 
levels of all genes, plotted as normed effect coefficients (NCs) (y-axis) 
against relative ranks (absolute rank divided by the number of genes; 
x-axis). Thick solid lines represent NCs; thin solid lines the values ex-
pected under the assumption of the null hypothesis and normality.
0.0 0.2 0.4 0.6 0.8 1.0
−
4
−
2
0
2
4
A
N
C:
 A
ll 
G
e
n
e
s
0.0 0.2 0.4 0.6 0.8 1.0
−
10
−
5
0
5
10
B
N
C:
 A
ll 
G
e
n
e
s
0.0 0.2 0.4 0.6 0.8 1.0
−
4
−
2
0
2
4
C
relative rank
N
C:
 A
ll 
G
e
n
e
s
Vogl et al. BMC Genomics 2010, 11:199
http://www.biomedcentral.com/1471-2164/11/199
Page 3 of 19
in Tyk2-/- relative to Wt cells, including for example
IFNγ- inducible protein 47 (IFI47), IFN regulatory factor
7 (IRF7), and 2'-5' oligoadenylate synthetase-like genes 1
and 2 (OASL1, OASL2), as well as three out of five
(STAT1, IRF1, and IRF7) IFN-responsive genes shown in
Figure 2.
Consistent with this, gene ontology (GO) analysis
showed that gene classes involved in immunity were sig-
nificantly downregulated in Tyk2-/- relative to Wt cells
(Table A1A). Interestingly, genes belonging to metabolic
gene classes showed higher expression in Wt relative to
Tyk2-/-, including genes in the classes "metabolism",
"lipid biosynthesis", "sterol biosynthesis", and "cholesterol
biosynthesis" (Table A1A). Overall, we observed a small
but significant shift in gene expression towards lower val-
ues in Tyk2-/- cells, suggesting the involvement of the
majority of metabolic genes in this shift (Figure 3A). This
relatively small but consistent effect can also be seen at
the level of individual genes, for example for the lipid
genes shown in Figure 2. Thus, in macrophages, Tyk2 is
not only required for basal expression of immune genes
but also for the maintenance of metabolic genes at a low
level of expression in an uninduced state.
In contrast to the relatively small number of differences
in baseline expression between Wt and mutant cells, LPS
treatment changed the transcriptional status of Wt mac-
rophages dramatically: 3622 genes (48%) were either up-
or downregulated upon exposure to LPS, including many
genes involved in immunity (effect of LPS treatment, Fig-
ure 1B; GEO accession number GSE19733). This massive
change in transcriptional status is also reflected in the
large distance between the observed curve and the curve
showing the theoretical expectation in Figure 1B. Among
the genes upregulated by LPS, several are known to also
be induced by cytokines, chemokines, or cellular stres-
sors, including the interleukins IL1A, IL1B, IL12A, the
IFN stimulated gene ISG20, and TNFα, as well as all five
IFN-responsive genes shown in Figure 2. In contrast,
genes involved in lipid metabolism were typically down-
regulated in Wt cells (see Figures 2 and 3B). Similar to the
situation at the basal level, this downward shift in expres-
sion involved almost all genes (Figure 3B).
In total, LPS treatment influenced 19 GO classes, with
strong upregulation of genes involved in inflammatory
responses and chemotaxis and downregulation of genes
involved in metabolism, indicating a negative relationship
between immune response and metabolism (Table B1B;
see Figure 3B for metabolic genes). In Tyk2 mutant cells,
however, only 2297 genes (30%) were influenced by LPS,
suggesting that Tyk2-/- cells respond overall much less to
LPS than Wt cells (GEO accession number GSE19733).
The observation that Tyk2-/- macrophages might
exhibit an impaired LPS response was confirmed when
we analyzed differences in how genotypes react to LPS
challenge: 1202 genes (16%) showed a difference in LPS
induction between Wt and Tyk2 mutant (effect of geno-
type × treatment interaction, Figure 1C, GEO accession
number GSE19733). For example, among the differen-
tially induced immune genes, LPS caused a much weaker
induction of the interferon-stimulated protein ISG20 and
the NO synthase NOS2 in Tyk2-/- than in Wt cells, but a
stronger induction of IFI47 and IRF7 relative to Wt (Fig-
ure 2).
Overall, we found that eleven classes of genes were dif-
ferentially induced by LPS between genotypes, including
weaker upregulation of genes involved in apoptosis and
negative cell cycle control and weaker suppression of
metabolic gene expression in Tyk2-/- relative to Wt cells
(Table C1C; see Figures 2 and 3C for metabolic genes).
Again, we found that this downward shift in gene expres-
sion involved the majority of all genes (Figure 3C). Most
notably, genes involved in "cholesterol biosynthesis", "ste-
rol biosynthesis", "steroid biosynthesis", and "lipid biosyn-
thesis" were much less strongly suppressed upon LPS
challenge in Tyk2-/- than in Wt macrophages. Metabolic
genes were therefore downregulated by LPS in Wt cells,
but their expression levels remained closer to the basal,
uninduced state in Tyk2-/- macrophages. RT-qPCR
broadly confirmed the effects of Tyk2 on immune and
metabolic genes (Additional File 1). Thus, Tyk2 is
required for LPS-induced upregulation of immune and
other genes and for the suppression of metabolic genes
upon LPS challenge (also see Additional File 1).
Transcription factor binding-sites
The expression of the about 25,000 genes in mammalian
genomes is regulated by many fewer transcription and
other regulatory factors. We therefore related our
microarray expression data to information on TFBSs
upstream of the transcription start site [14]. Since TFBSs
are often short and relatively uninformative, and because
many putative TFBSs are biologically irrelevant, we
extracted sequences from the 5' upstream region (5'UR)
that are conserved between human and mouse, as such
phylogenetic conservation might indicate functional
importance in transcriptional control. This bioinformat-
ics analysis identified 174 classes of putative 5'UR TFBSs.
At the basal level, only genes that contain the IRF/ISRE
TFBS were differentially regulated between genotypes;
genes with GAS elements showed no significant differ-
ence between genotypes (Figure 4A, Table A2A, Addi-
tional File 2). Since the IRF/ISRE element is responsive to
the ISGF3 complex, genes containing such an element are
likely candidate targets of IFNα/β signaling. Tyk2-/- mac-
rophages had on average an approximately 1.4 times
reduced expression of genes with an IRF/ISRE TFBS as
compared to Wt cells (Figure 4A, Table A2A, Additional
File 2). Unlike the situation for metabolic genes, this dif-
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Figure 2 Effects of Tyk2 and LPS on relative expression levels of immune genes and lipid genes. Representative examples of the effects of gen-
otype (Wt vs.Tyk2-/- (Tk)) at the basal level (0) or after six hours of LPS treatment (6). Five genes (STAT1, IRF1, CCL5, IRF7, NOS2) are immunity annotated 
and IFN-responsive genes; four genes (CRAT, FADS1, FASN, MVD) are annotated for lipid metabolism. Expression levels, as determined by microarray 
fluorescence intensities, are shown relative to the mean basal level in the Wt. Error bars represent standard errors. All genes were validated with RT-
qPCR (see Materials and Methods).
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Table 1: Results of gene ontology analysis using the "biological process" annotation
GO category # genes ER NC p-value
(A)
humoral defense 
mechanism sensu 
Vertebrata
11 1.58 4.3 0
antigen presentation 11 1.54 4.02 0
defense response 46 1.34 2.72 0
immune response 102 1.28 2.31 0
positive regulation of 
transcription
DNA-dependent 13 1.19 1.65 0.0013
regulation of 
apoptosis
45 1.11 0.94 0.0005
protein ubiquitination 78 1.06 0.58 0.0049
protein modification 71 1.06 0.57 0
transcription 449 1.04 0.34 0
regulation of 
transcription 
DNA.dependent
586 1.03 0.29 0
transport 576 0.97 -0.29 0.0002
electron transport 138 0.95 -0.49 0.002
metabolism 151 0.92 -0.8 0
sodium ion transport 22 0.88 -1.2 0.0025
biosynthesis 24 0.87 -1.26 0.0009
fatty acid biosynthesis 15 0.85 -1.57 0.0011
lipid biosynthesis 34 0.83 -1.77 0
Vogl et al. BMC Genomics 2010, 11:199
http://www.biomedcentral.com/1471-2164/11/199
Page 6 of 19
steroid biosynthesis 20 0.83 -1.79 0
cholesterol 
biosynthesis
12 0.79 -2.21 0
sterol biosynthesis 13 0.77 -2.5 0
(B)
inflammatory 
response
46 2.24 7.55 0
chemotaxis 30 2 6.48 0
immune response 102 1.93 6.18 0
sensory perception 42 1.64 4.66 0
defense response to 
bacteria
11 1.63 4.61 0.0001
defense response 46 1.37 2.97 0
cell surface receptor 
linked signal 
transduction
32 1.28 2.28 0.001
sensory perception of 
smell
70 1.25 2.08 0
cell proliferation 42 1.24 2.03 0.0008
signal transduction 222 1.21 1.79 0
regulation of 
apoptosis
45 1.2 1.73 0
G-rotein coupled 
receptor protein 
signaling pathway
166 1.15 1.32 0
regulation of 
transcription
119 1.1 0.87 0
regulation of 
transcription 
DNA.dependent
586 1.04 0.38 0
Table 1: Results of gene ontology analysis using the "biological process" annotation (Continued)
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ference between genotypes was not caused by the major-
ity of genes, but by a few genes with much higher
expression in Wt than in Tyk2-/- (Figure 4A). Moreover,
the expression of several immune genes, including Z-
DNA binding protein 1 (ZBP1), guanylate binding pro-
tein 3 (GBP3), IFN-induced transmembrane protein 3
(IFITM3), and the interleukin 15 receptor α (IL15RA),
was about three times higher in Wt than in Tyk2-/- cells
(Additional File 1, GEO accession number GSE19733).
LPS treatment influenced seven classes of genes in Wt
macrophages (Figure 4B, Table B2B, Additional File 2),
with two of them containing putative binding-sites for
electron transport 138 0.87 -1.26 0
metabolism 151 0.82 -1.91 0
lipid metabolism 59 0.79 -2.21 0
lipid biosynthesis 34 0.77 -2.49 0
fatty acid metabolism 32 0.71 -3.15 0
(C)
negative regulation of 
progression through 
cell cycle
26 1.17 0.95 0.0022
anti apoptosis 30 1.17 0.92 0.0015
metabolism 151 0.92 -0.47 0.0009
protein biosynthesis 180 0.92 -0.52 0
cell proliferation 42 0.87 -0.8 0.0021
fatty acid metabolism 32 0.85 -0.95 0.0015
rRNA processing 29 0.85 -0.97 0.0019
lipid biosynthesis 34 0.84 -1.02 0.0004
steroid biosynthesis 20 0.83 -1.09 0.0037
sterol biosynthesis 13 0.8 -1.34 0.0039
cholesterol 
biosynthesis
12 0.79 -1.43 0.003
Within the "biological process" annotation, gene classes (412 in total) were separately contrasted with all other classes using t-tests on 
standardized coefficients. (A) Basal differences between genotypes, (B) LPS induction in Wt, and (C) differences between genotypes in LPS 
induction (genotype by treatment interaction). ER, approximate mean expression ratio, NC, mean normed coefficients.
Table 1: Results of gene ontology analysis using the "biological process" annotation (Continued)
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unknown transcription factors. Similar to the baseline
differences in expression between genotypes, genes with
the IRF/ISRE TFBS (e.g., gram negative binding protein 3
(GNBP3), cluster of differentiation 274 (CD274), and
IL15RA) were strongly upregulated after six hours of LPS
treatment. These genes were followed by an uncharacter-
ized class of genes, either with CHX10 TFBS (e.g., β-site
APP cleaving enzyme 1 (BACE1), the 14-3-3 gene Strati-
fin, the Myc associated factor X (MAX), and CD38) or
containing homeodomain transcription factor IPF1/
PDX1 motifs (e.g., Stratifin, the tripartite motif gene
TRIM21, and the zinc finger transcription factor Zfp281).
To our knowledge, neither CHX10 TFBS nor IPF1/PDX1
motifs have previously been implicated in the LPS
response. Genes containing a TATA box were also signifi-
cantly upregulated upon LPS exposure (especially the
LIM homeodomain factor LHX4 and TNFα). Further-
more, we found evidence for weak upregulation of genes
with conserved NF-AT motifs (Table B2B), with AP-1/
Jun and c-REL consensus sequences (using a significance
level of α = 0.01 - see Methods for definition of cutoff cri-
teria; Additional File 2), and with NFκB motifs (using α =
0.05; Additional File 2). Interestingly, we failed to observe
LPS-induced downregulation of any gene class (either
using FDR = 0.05 or α = 0.01 as cutoffs; Table B2B, Addi-
tional File 2).
Six classes of genes differed in their induction by LPS
between genotypes, and for all these classes induction by
LPS was lower in Tyk2-/- than in Wt cells (Table C2C,
Additional File 2). Genes containing the pituitary-specific
transcription factor POU1F1 motif showed the most pro-
nounced differences in mean expression, whereas genes
with a IPF1/PDX1 motif (especially Stratifin) or a TATA
box (especially LHX4 and NOS2) showed the highest sta-
tistical significance (Table C2C, Additional File 2). How-
ever, despite these genotypic differences in inducibility,
LPS induced on average similar expression of genes with
an IRF/ISRE TFBS in Wt and Tyk2-/- macrophages (Fig-
ure 4C, Table C2C, Additional File 2). Upon LPS chal-
lenge, Wt and Tyk2-/- cells therefore reached
qualitatively and quantitatively similar expression levels
of genes that contain the IRF/ISRE TFBS. These results
suggest that Tyk2 is functionally required for the baseline
expression of genes with an IRF/ISRE TFBS, but dispens-
able for their LPS-induced upregulation.
Since the above analysis of IRF/ISRE TFBSs was based
on very stringent criteria and thus likely to miss many
known IFN-inducible genes (see Methods), we also pro-
duced a list of 187 IFN-responsive genes from the litera-
ture and asked how many of those genes showed
expression changes in our microarray experiment and
contain IRF/ISRE or GAS TFBSs.
After filtering of lowly expressed genes, 137 genes
remained in the analysis. At the basal level, we found that
this class of IFN-inducible genes was on average down-
regulated relative to all other genes in Tyk2-/- versus Wt
macrophages (Additional File 3). While the mean expres-
sion ratios relative to Wt were quite small, the average
difference was caused by a few genes of large effect, with
23 genes being significantly differentially expressed
(Additional File 3). The genes that showed the largest
expression differentials were IRF7, IFN-inducible pro-
teins 1 and 205 (IFI1, IFI205), and transporter associated
with Ag processing 1 (TAP1), thereby confirming that
Tyk2 is required for baseline expression of IFN-inducible
genes. Upon LPS stimulation, IFN-inducible genes were
on average much more strongly upregulated than other
genes (74 genes in Wt; Additional File 3). Again, this pat-
tern was mainly caused by a few genes with extreme
effects, including IL1B, chemokine (C-C motif ) ligands 2
and 7 (CCL2, CCL7), and chemokine (C-X-C motif )
ligand 2 (CXCL2). As in our analysis of genes with the
IRF/ISRE TFBS, the average induction of IFN-inducible
genes by LPS was similar between Tyk2-/- and Wt mac-
rophages, with both cell types reaching qualitatively iden-
tical expression levels (Additional File 3). To validate
Figure 3 Effects of Tyk2 and LPS on metabolic gene expression. 
Effects of (A) Tyk2 genotype (Wt minus Tyk2-/-), (B) LPS treatment (6 
hours of LPS minus control), and (C) genotype by treatment interaction 
(difference in LPS induction between Wt and Tyk2-/-) on expression 
levels of genes annotated for metabolism, plotted as NCs (y-axis) 
against relative ranks (absolute rank divided by the number of genes; 
x-axis). Thick solid lines represent NCs; thin solid lines the values of all 
genes (see Figure 1) in order to highlight effects on metabolic genes 
relative to all genes analyzed.
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these microarray results we performed RT-qPCR on nine
IFN-inducible genes and found a good agreement with
respect to approximate fold induction (Additional File 1).
IFN-responsive genes contained significantly more
IRF/ISRE and GAS TFBSs than other genes, although
enrichment was only modest for the latter. The criteria of
inclusion, i.e. the length of the 5'UR and the counting of
only TFBSs conserved between human and mouse influ-
enced the results considerably. As expected, conservation
of TFBSs among species decreased the number of false
positives, whereas a long 5'UR stretch or no conservation
increased it (Additional File 3).
Table 2: Analysis of putative 5'UR TFBSs
TFBS # genes ER NC p-value
(A)
IRF/ISRE 40 1.41 3.20 0.0011
(B)
IRF/ISRE 40 1.53 3.99 0.0001
127 35 1.19 1.60 0.0006
CHX10 160 1.09 0.80 0.0001
IPF1 = PDX1 108 1.08 0.72 0.0010
TATA 280 1.07 0.67 0.0005
174 176 1.06 0.56 0.0009
NF-AT 519 1.03 0.25 0.0011
(C)
115 33 1.13 0.73 0.0006
POU1F1 49 1.12 0.65 0.0019
IPF1 = PDX1 108 1.08 0.45 0.0003
FOXF2 171 1.07 0.40 0.0018
CHX10 160 1.06 0.35 0.0010
TATA 280 1.06 0.33 0.0005
We assigned genes to 174 classes of putative TFBSs, either identified by their name, the major transcription factor binding to them, or their 
number in Xie et al. [14]. The table shows the number of genes in each TFBS class, approximate mean expression ratios (ER), mean normed 
coefficients (NC), and p-values from t-tests. (A) Basal differences between genotypes, (B) LPS induction in Wt, and (C) differences between 
genotypes in LPS induction (genotype by treatment interaction).
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3' UTR regulatory elements
As mRNA levels are not only known to be regulated by
5'UR TFBSs, but also post-transcriptionally by regulatory
elements in the 3'untranslated region (UTR), we were
interested in relating the observed expression differences
to putative 3'UTR regulatory sequences. We focused on
two not mutually exclusive classes of regulatory
sequences: (i) conserved 3'UTR motifs and (ii) 3'UTR
microRNA (miRNA) cognate sequences.
To examine motifs in the 3'UTR we analyzed our data
with respect to 175 classes of conserved putative 3'UTR
regulatory sequences defined by Xie et al. [14] (Table 3,
Additional File 4). As compared to 5'UR TFBSs, we found
many more gene classes to be differentially expressed
(Table 3, Additional File 4). This might simply be due to a
larger number of genes containing specific 3'UTR motifs
than 5'UR TFBSs. Alternatively, 3'UTR elements might
be more conserved, or easier to detect, than 5'UR TFBSs.
We observed four classes of motifs that were differentially
regulated between genotypes at the basal level (Table
A3A), 37 that were up- or downregulated after LPS treat-
ment in Wt (Table B3B), and three that showed differ-
ences in LPS inducibility between genotypes (Table C3C).
Genes with AU-rich elements (m2/ARE) were the most
significantly upregulated upon LPS treatment (Table B3B,
Additional File 5). Similar to what we observed for IFN-
responsive genes or those with IRF/ISRE TFBSs, this pat-
tern was mainly caused by a few genes with extreme
effects on expression, such as IL1A, IL1B, CXCL2, and
TNFα, which were among the most responsive genes
(GEO accession number GSE19733). In contrast, LPS
caused downregulation of a large class of genes contain-
ing poly-A signal (m1/poly-A) motifs (Table B3B). How-
ever, genes with m2/ARE or m1/poly-A motifs neither
differed in baseline expression, nor in LPS inducibility
between Wt and Tyk2-/- macrophages.
A special class of 3'UTR regulatory elements important
in the regulation of gene expression are the targets of
miRNAs, short single-stranded RNA molecules consist-
ing of 21-24 nucleotides. To analyze miRNA cognate
motifs we related known miRNAs from miRBase http://
www.mirbase.org/[15-17] to the octameric sequences in
[14]. Using this approach, we were able to uniquely define
different cognate 3'UTR sequences (which might other-
wise have been lumped into a single class in the analysis
above). Out of 111 such sequences, we found three
miRNA cognate motif classes to be differentially
expressed at the basal level, three classes to be influenced
by LPS in Wt cells, and three classes to differ in their LPS
inducibility between genotypes (Additional File 6). As far
as we know, none of these miRNA motifs has been previ-
ously implicated in the IFN or LPS response. However,
since conserved 3'UTR elements and miRNA consensus
sites are still poorly characterized, it is difficult to func-
tionally interpret these results. Nonetheless, our observa-
tions provide strong evidence for an involvement of such
regulatory sequences in the LPS response of Wt and
Tyk2-/- macrophages.
Discussion
In this microarray study we have investigated the role of
the JAK protein kinase family member Tyk2 in basal and
LPS-induced gene expression in mouse peritoneal mac-
rophages. While several previous studies have demon-
strated that Tyk2 is an important regulator of immune
and inflammatory responses [10,12,18], here we show
how Tyk2 globally affects genome-wide transcript levels.
At the basal uninduced level, we found subtle but sig-
nificant differences in gene expression between Wt and
Tyk2-/- macrophages. Relative to Wt, Tyk2-deficient
macrophages displayed reduced expression of many
immune genes, in particular some genes that contain IFN
response elements (IRF/ISRE) in their 5'UR, suggesting
that Tyk2 deficiency compromises the type I IFN (i.e.,
Figure 4 Effects of Tyk2 and LPS on genes with IRF/ISRE TFBS. Ef-
fects of (A) Tyk2 genotype (Wt minus Tyk2-/-), (B) LPS treatment (6 
hours of LPS minus control), and (C) genotype by treatment interaction 
(difference in LPS induction between Wt and Tyk2-/-) on expression 
levels of genes containing the IRF/ISRE TFBS, plotted as NCs (y-axis) 
against relative ranks (absolute rank divided by the number of genes; 
x-axis). Thick solid lines represent NCs; thin solid lines the values of all 
genes (see Figure 1) in order to highlight the effects on genes with IRF/
ISRE TFBS relative to all genes analyzed.
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Table 3: Analysis of 3'UTR regulatory sequences
3'UTR motif gene # ER NC p-value
(A)
m57 110 1.04 0.39 0.0037
m11 623 0.98 -0.23 0.0026
m43 254 0.96 -0.33 0.0009
o7 207 0.96 -0.33 0.0058
(B)
m53 42 1.30 2.60 0.0076
o34 75 1.13 1.22 0.0006
m35 54 1.13 1.18 0.0026
m103 41 1.11 1.05 0.0048
m33 119 1.11 1.04 0.0026
m95 56 1.11 1.03 0.0004
m16 213 1.10 0.99 0.0000
o25 105 1.09 0.86 0.0011
m85 82 1.09 0.84 0.0043
m2/ARE 675 1.09 0.82 0.0000
m67 164 1.07 0.68 0.0004
o18 278 1.07 0.65 0.0001
m50 108 1.07 0.64 0.0081
m100 70 1.06 0.60 0.0079
o43 142 1.05 0.49 0.0021
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m30 85 1.05 0.49 0.0133
m70 136 1.05 0.48 0.0108
o12 196 1.05 0.48 0.0012
m24 332 1.05 0.47 0.0001
o15 253 1.04 0.43 0.0011
m3 481 1.04 0.43 0.0000
m20 262 1.04 0.40 0.0024
o38 142 1.04 0.38 0.0063
m29 232 1.04 0.37 0.0013
m41 224 1.04 0.36 0.0025
o32 155 1.04 0.36 0.0067
m13 1015 1.03 0.30 0.0000
m4 625 1.03 0.29 0.0000
o21 363 1.03 0.26 0.0011
m19 308 1.02 0.25 0.0028
m9 942 1.02 0.24 0.0000
m31 347 1.02 0.21 0.0018
m25 488 1.02 0.21 0.0006
m8 337 1.02 0.17 0.0077
m26 383 1.02 0.15 0.0017
m5 1175 1.01 0.06 0.0000
m1/poly-A 1938 0.95 -0.54 0.0091
Table 3: Analysis of 3'UTR regulatory sequences (Continued)
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IFNα/β) response. This observation confirms previous
findings demonstrating that IFNα/β signaling is reduced
in Tyk2-/- mice and that IFNα4 and IFNβ mRNA levels
are diminished in Tyk2 null macrophages at the basal
level [10-12].
In addition to the ISGF3 complex, type I IFNs also acti-
vate STAT1 homodimers, which induce gene expression
via IFNγ activated sequence (GAS) elements. Further-
more, STAT1 homodimers are strongly activated by
IFNγ, whose production and signaling is partially
impaired in the absence of Tyk2 [10-12]. It is still contro-
versial whether macrophages can produce significant
amounts of biologically active IFNγ [19], however, cells
might have been exposed to IFNγ during the generation
procedure. We were therefore interested to determine if
genes containing GAS TFBSs are also influenced by the
absence of Tyk2. In contrast to the involvement of IRF/
ISRE TFBS in the Tyk2 mediated response, we failed to
find evidence for differential expression of genes contain-
ing GAS elements. Since the mouse genome contains
very many such elements, not all of which are involved in
gene regulation, it is possible that our bioinformatic anal-
ysis failed to find those GAS elements that are biologi-
cally relevant. Thus, while in our study reduced baseline
expression of immunity related and IFN-responsive genes
in Tyk2-deficient macrophages seems to be mainly medi-
ated by IRF/ISRE TFBSs, the role of Tyk2 in GAS-driven
gene regulation deserves further investigation.
We also found that Tyk2 is required for the full
response of genes upon LPS challenge, as expected based
on previous experiments [10,12]. LPS challenge affected
the expression of about 48% of all genes in Wt cells,
including many immune genes, but influenced only about
30% of all genes in Tyk2-/- cells. Consequently, Tyk2-defi-
cient macrophages failed to induce many LPS-responsive
transcripts, in particular immunity related genes. Sur-
prisingly, however, IFN-responsive genes did not follow
this trend: LPS challenge increased the expression of IFN-
inducible genes to a similar extent in Wt and Tyk2-/-
macrophages, suggesting that Tyk2 might not be critical
for LPS-induced upregulation of IFN-responsive genes.
Thus, although previous observations have found
reduced levels of IFNα4 and IFNβ in Tyk2-/- mac-
rophages [12], a high proportion of LPS-induced type I
IFN signaling might be largely independent of Tyk2.
Several previous studies have examined IFN mediated
immune and inflammatory transcription in bone marrow
derived mouse macrophages (BMDMs) using microar-
rays [20,21]. Thomas et al. [20] studied Wt and IFNβ-/-
cells at the basal level and after one and three hours of
LPS treatment using Affymetrix microarrays. Many
genes whose baseline levels were reduced by lack of IFNβ
also had significantly lower levels in Tyk2-/- cells in our
experiment. The overall correlation between expression
differences for IFNβ-/- vs. Wt [20] and Tyk2-/- vs. Wt
(our study) was r = 0.41 (see Additional File 7). Hence, the
effect of IFNβ deficiency on baseline gene expression is
similar to the lack of Tyk2. Thomas et al. [20] also identi-
fied many LPS-induced genes in Wt that we found to be
induced in our study (overall correlation r = 0.48 - see
Additional File 7). However, while IFNβ-/- macrophages
showed an impaired LPS response for many IFN depen-
dent genes [20], induction of these genes by LPS was gen-
erally unimpaired in Tyk2-/- macrophages in our
experiment. A comparison of LPS inducibility between
IFNβ-/- and Tyk2-/- macrophages only revealed a weak
correlation of r = 0.03 (Additional File 7). Tyk2 therefore
seems to be required for basal expression of IFNβ target
genes but not for their induction by LPS. In another
microarray study by Fleetwood et al. [21], genes whose
basal expression levels depend on intact type I IFN sig-
naling were characterized in BMDMs, either cultivated in
the presence of macrophage colony stimulating factor
(M-CSF, or CSF1) or granulocyte macrophage colony
stimulating factor (GM-CSF). Most genes that were
downregulated in IFNAR1-/- genotypes in both M-CSF
and GM-CSF BMDMs were also decreased in Tyk2-/- rel-
ative to Wt cells in our experiment (Additional File 8),
thus confirming our observation that Tyk2 is involved in
basal IFNα/β signaling. Furthermore, the effects of basal
(C)
m91 66 1.1 0.56 0.0046
m13 1015 1.01 0.06 0.0016
m9 942 1.01 0.06 0.0016
A total of 175 3'UTR motis were identified as described in Xie et al. [14]. The table shows the number of genes in each class of motif, 
approximate mean expression ratios (ER), mean normed coefficients (NC), and p-values from t-tests. (A) Basal differences between genotypes, 
(B) LPS induction in Wt, and (C) differences between genotypes in LPS induction (genotype by treatment interaction).
Table 3: Analysis of 3'UTR regulatory sequences (Continued)
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type I IFN signaling on gene expression in the thioglyco-
late-elicited peritoneal macrophages used in our study
were similar to those observed in the BMDMs used in
[20] and [21].
Interestingly, our study also provides evidence for a
previously unknown role of Tyk2 in regulating metabo-
lism. Tyk2 mutant macrophages showed enhanced base-
line expression of metabolic genes relative to Wt cells,
including genes involved in steroid, sterol, and lipid
metabolism. Upon LPS treatment, metabolic gene
expression was strongly decreased in Wt macrophages,
while in Tyk2-/- macrophages expression of these genes
remained relatively unchanged. Thus, the differential LPS
response of Wt versus mutant macrophages increased
differences in gene expression already present at the basal
level: the relatively low expression of metabolic genes in
Wt cells was strongly suppressed by LPS, whereas in
Tyk2-/- cells LPS suppressed the relatively high expres-
sion of metabolic genes much less. This effect pertained
to most genes in the GO class "metabolism", and in par-
ticular to genes belonging to the classes "cholesterol bio-
synthesis", "sterol biosynthesis", "steroid biosynthesis",
and "fatty acid metabolism" Taken together, these results
suggest an involvement of Tyk2 in the regulation of gen-
eral metabolism and of lipid metabolism in particular.
Tyk2 might thus be an important mediator of the connec-
tion between immunity and metabolism.
Two not mutually exclusive mechanisms might account
for the effects of Tyk2 on metabolic gene expression. On
the one hand, Tyk2/IFN signaling might directly lead to
decreased metabolism, possibly because upregulation of
immune function shuts down other energetically
demanding processes [22,23]. On the other hand, Tyk2
might exhibit pleiotropic effects on immunity and metab-
olism that are largely independent: a canonical IFN sig-
naling function of Tyk2 might be associated with an
independent role in metabolic regulation. Potentially
consistent with either model, we observed that LPS treat-
ment of macrophages reduces the expression of mito-
chondrial genes and that this downregulation is impaired
in Tyk2-/- cells relative to Wt (GO annotation "cellular
component", GO class "mitochondrion"; results not
shown). Remarkably, dysfunctional mitochondrial respi-
ration has been shown for Tyk2-deficient pro-B cells [24].
In a similar vein, Pitroda et al. [25] found that STAT1
knockdown is associated with alterations in the expres-
sion of genes involved in energy metabolism, including
glycolysis, oxidative phosphorylation, and the citrate
cycle. Tyk2/IFN signaling might thus regulate metabo-
lism by targeting mitochondrial processes via STAT1.
Notably, we observed a particularly pervasive effect of
Tyk2 on lipid and fatty acid metabolism in macrophages.
This result fits well with previous studies that have
reported intricate but not well understood interactions
between immunity, inflammation, and lipid metabolism
[for reviews see [21,22]]. For example, lipids can be
sensed by and act on Toll-like receptors (TLRs) such as
TLR4, probably because TLR agonists like LPS contain a
biologically active lipid moiety [see [23]]. Moreover, mac-
rophages and adipocytes are derived from a common
ancestral progenitor and share several transcriptional fea-
tures, with macrophages expressing some adipocyte spe-
cific genes and adipocytes expressing several macrophage
specific genes, including IL6 and TNFα [see [23], and ref-
erences therein]. However, little is currently understood
about the downstream effects of impaired IFN signaling
on lipid metabolism, as we have observed them in our
experiments.
Although the biological details remain unclear, several
studies have established a link between IFN signaling,
innate immunity, and lipid metabolism. Mice deficient for
interleukin 1 receptor antagonist α (IL1Ra), for instance,
are lean, have impaired body fat accumulation, and
exhibit reduced lipoprotein lipase activity [26], and TNFα
can increase lipolysis and promote apoptosis of adipo-
cytes [27]. Moreover, Zwaferink et al. [28] have recently
reported that key lipogenic enzymes, including fatty acid
synthase (FASN), are suppressed in IFNβ treated mouse
BMDMs. Since we have observed a similar downregula-
tion in Tyk2 mutant macrophages, and because Tyk2
deficiency is known to decrease IFNβ levels [12], it might
be possible that Tyk2 influences lipid metabolism
through a basal feed-forward loop between IFNβ and
Tyk2.
Our findings are also consistent with our previous
observation that Tyk2 modulates metabolic proteins in
BMDMs before and after LPS treatment [29]. However, it
remains possible that isolated mouse macrophages dis-
play somewhat abnormal metabolic behavior. We found
most metabolic genes to be suppressed upon LPS treat-
ment in Wt macrophages, but in vivo results suggest that
Wt mice become hypermetabolic ninety minutes after
LPS injection [30]. Thus, future studies will need to
examine the detailed role of Tyk2 in regulating metabo-
lism, both in macrophages and other cell types as well as
in vivo.
In addition to the IRF/ISRE TFBS already mentioned
above, our study also identified several other TFBSs that
might be involved in the immune and inflammatory
response. In particular, we found several genes with 5'UR
binding-sites for transcription factors that have not yet
been implicated in immunity. For example, some genes
with a TATA box were upregulated by LPS. Unfortu-
nately, we cannot decipher this "regulatory code" in mam-
mals with current bioinformatics means, although it
might be conserved over quite large phylogenetic dis-
tances [31]. We also observed five known and one
unknown TFBS to be correlated with induction differ-
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ences between Wt and Tyk2-/- cells. While further analy-
sis will be required to examine the effect of these motifs,
we generally observed similar GO classes to be upregu-
lated after six hours of LPS as Nilsson et al. [32] who
studied the expression of genes and gene regulation via
5'UR TFBS in BMDMs after seven hours of LPS stimula-
tion.
Finally, we related our results to information on puta-
tive 3'UTR elements. We found many more genes per
3'UTR element than per 5'UR TFBS, possibly because the
3'UTR is evolutionarily more conserved than the 5'UR or
because regulation at the 3'UTR is more pleiotropic than
at the 5'UR. Overall, our results provide strong evidence
for the involvement of 3'UTR elements in the LPS
response and in the differential regulation of expression
between genotypes. Several classes of conserved 3'UTR
regulatory sequences and 3'UTR miRNA cognate
sequences were differentially regulated between geno-
types, in response to LPS, and in terms of LPS inducibility
between Wt and Tyk2 mutant cells. Most notably, LPS
strongly induced expression of genes with AU-rich ele-
ments (m2/ARE), which have already previously been
implicated in innate immunity [33,34]. In contrast,
among the miRNA cognate motifs that were differentially
regulated in our experiment, none has a known function.
Thus, since 3'UTR conserved elements and miRNA con-
sensus sites are still poorly annotated and characterized,
it is difficult to biologically interpret these results. Never-
theless, it has become clear in recent years that 3'UTR
elements and miRNA cognate sequences are highly
important in regulating gene expression, and it will there-
fore be interesting to explore their potential role in
immune and inflammatory transcription.
Conclusions
We conclude that Tyk2 function is required for the full
transcriptional response upon LPS challenge, but dis-
pensable for the LPS induction of IFN-responsive genes.
Although it remains presently unclear why Tyk2 mainly
mediates baseline but not LPS-induced type I IFN signal-
ing, we suggest that Tyk2 maintains IFN-responsive genes
in a primed, "ready to go" state, with factors other than
Tyk2 mediating their induction upon immune challenge.
Moreover, we conclude that Tyk2 plays a major but previ-
ously unknown role in the regulation of metabolism,
especially lipid metabolism. Our data suggest that Tyk2 is
not only critically required for the downregulation of
baseline expression of many metabolic genes, but also for
their further LPS-mediated suppression. While these
results deserve in-depth future analysis, they clearly
strengthen the previously made case for intricate connec-
tions between IFN signaling and metabolism and provide
evidence for a role of Tyk2 in this connection. A better
understanding of the relationship between immunity and
metabolism will also likely be important for improving
therapeutic interventions that target immune diseases as
well as metabolic disorders.
Methods
Mice and macrophages
C57BL/6 wildtype (Wt) mice (Mus musculus) were pur-
chased from Charles River Laboratories International,
Inc. (Wilmington, MA, USA). Tyk2-/- mice are described
in [10] and were backcrossed for ten generations into the
C57BL/6 background. Mice were housed and bred under
specific pathogen free conditions according to FELASA
guidelines. All animal experiments were discussed with
and approved by the institutional ethics committee and
were carried out in accordance with protocols approved
by Austrian laws (GZ 68.205/67-BrGT/2003; GZ 68.205/
0204-C/GT/2007) and European directives.
Thioglycolate-elicited peritoneal macrophages were
isolated from sex- and age-matched mice (males, 8-10
weeks old) as described in [35]. Cells from 2-3 mice per
genotype were pooled for each of the three independent
replicate experiments. 4 × 106 cells were plated out on 6
cm cell culture dishes (BD Falcon) and grown under stan-
dard conditions (37°C, 5% CO2) in DMEM medium
(Invitrogen) supplemented with 5% fetal calf serum
(FCS), 100 mg/mL penicillin, 100 U/mL streptomycin, 2
mM L-glutamine and 50 μM β-mercaptoethanol. The day
after isolation, cells were stimulated with 100 ng/mL LPS
(E. coli serotype 055:B5, Sigma) or medium only (con-
trol), respectively, for six hours. For each combination of
genotype (Wt versus Tyk2-/-) and treatment (control ver-
sus LPS) we carried out three independent replicate
experiments.
Microarrays and RT-qPCR
For microarrays and RT-qPCR, total RNA was isolated
using TRIZOL reagent (Invitrogen) according to the
manufacturer's instructions. RNA concentration and
integrity were determined by capillary electrophoresis
(Agilent Technologies).
Total RNA (2 μg) was reverse transcribed using the
iScript First Strand cDNA Synthesis Kit (Bio-Rad) and
hybridized to the CodeLink Mouse Whole Genome Bio-
array http://www.appliedmicroarrays.com/ according to
the manufacturer's protocols. Arrays were scanned with a
GenePix Array Scanner 4000B and GenePix Pro 4.0 soft-
ware (Axon Instruments, Inc.). Data were prepared for
statistical analysis (see below) with CodeLink Expression
Analysis software http://www.appliedmicroarrays.com/.
A gene was recorded as expressed if its unnormalized flu-
orescence intensity value exceeded 25 (see below). For
these expressed genes, we log-transformed their intensity
values and normalized them, separately for each array, to
a mean of zero and a variance of one. Genes with missing
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annotation and duplicate gene entries were removed
before analysis;7546 genes of the approximately 30,000
genes on the microarray remained after filtering. The
microarray dataset has been deposited at Gene Expres-
sion Omnibus (GEO; http://www.ncbi.nlm.nih.gov/geo/
with accession number GSE19733).
To validate the expression data from the microarrays
we performed reverse transcription-quantitative poly-
merase chain reactions (RT-qPCR) for about 170 genes
including several IFN-inducible genes (Additional File 1).
RNA (3 μg/60 μl) was reverse transcribed using the
iScript First Strand cDNA Synthesis Kit (Bio-Rad). Taq-
man qPCR Low Density Custom Arrays (Applied Biosys-
tems) were used to validate the microarray data, either in
48 well (samples in duplicates) or in 96 well (single sam-
ples) format. 5 μl cDNA (corresponding to 250 ng input
RNA) were used in a 100 μl mastermix per sample-load-
ing port, containing 5 mM MgCl2, 200 μM of each dNTP
(MBI Fermentas), 1 × ROX reference dye (Invitrogen), 4
Units HotFire DNA polymerase (Solis Biodyne), and 1 ×
reaction buffer B (Solis Biodyne). RT-qPCR was per-
formed on a ABI PRISM 7900 HT machine (Applied Bio-
systems) using the following cycling conditions: initial
denaturation at 95°C for 12 min, 40 cycles of 95°C for 15
sec and 60°C for 1 min.
Validation of selected addional genes (mixed GO anno-
tations) and genes involved in lipid metabolism was per-
formed with single RT-qPCR assays. RNA (1 μg/20 μl)
was reverse transcribed as described above. For assays
using probes, we used 0.5 -2 μl cDNA (dependent on the
gene analyzed) in a 25 μL mastermix, containing 2.5 mM
MgCl2, 200 μM of each dNTP (MBI Fermentas), 300 nM
primer, 100 nM probe, 1 Unit HotFire DNA polymerase
(Solis Biodyne), and 1 × reaction buffer B (Solis Biodyne).
For Qiagen assays, we used 0.5-2 μl cDNA in a 25 μL mas-
termix, containing 2.5 mM MgCl2, 200 μM of each dNTP
(MBI Fermentas), 1 × QuantiTect primer assay (Qiagen),
0.2 × EvaGreen (Biotium), 1 Unit HotFire DNA poly-
merase (Solis Biodyne), and 1 × reaction buffer B (Solis
Biodyne). RT-qPCR was performed on a Mastercycler
realplex (Eppendorf ) machine using the following cycling
conditions: initial denaturation at 95°C for 15 min, 40
cycles of 95°C for 20 sec and 60°C for 1 min. For Qiagen
assays, melting curve analyses were performed in order to
check specificity. For details on RT-qPCR assays see
Additional File 1.
The resulting data were analyzed using SDS 2.2
(Applied Biosystems) or realplex (Eppendorf ) software
and the statistical package R [36]. To compare microarray
and RT-qPCR data we used log-transformed fluorescence
intensity data. To standardize the RT-qPCR data we sub-
tracted the mean Ct values of two endogenous control
genes, ubiquitin-conjugating enzyme E2D 2 (UBE2D2)
and hypoxanthine phosphoribosyltransferase (HPRT),
from the RT-qPCR Ct values of the focal genes analyzed
by Taqman qPCR Low Density Custom Arrays. For single
RT-qPCR assays, the standard curve method was used to
calculate the log expression levels, and values for the
endogenous control gene UBE2D2 were subtracted from
those of the focal genes. Thus, the microarray and RT-
qPCR values were expected to be approximately propor-
tional or inversely proportional, respectively, to the log of
the mRNA concentrations of the focal genes. We found a
good, approximately linear relationship between log
microarray fluorescence intensities and normalized RT-
qPCR delta Ct values for medium to highly expressed
genes, while at lower levels we generally observed over-
whelming background noise (Additional File 1). Impor-
tantly, we found a good agreement in terms of
approximate fold induction between array and RT-qPCR
data in general, and especially for IFN-inducible genes,
genes involved in lipid metabolism, and five other genes
(Additional File 1).
In order to check the experiment used for microarray
analysis for effective LPS stimulation and for the
expected differences between Wt and Tyk2-/- cells, IFNβ
mRNA expression was monitored with RT-qPCR (data
not shown). IRF7 and IRF1 were included in the valida-
tion experiments (Additional File 1). mRNA expression
patterns of all three genes were as expected [12]. In addi-
tion, microarray results for TNFα and NOS2 expression
confirmed our previous findings [10,12].
Analysis of single genes and gene ontology
To analyze the effects of genotype and LPS treatment on
gene expression we used Analysis of Variance (ANOVA).
For each gene, log-transformed normalized data were
used in an univariate fully factorial two-way ANOVA,
with genotype (Wt versus Tyk2-/-) and LPS treatment
(untreated control versus LPS) as fixed factors:
where ygti is the gti-th expression level for each gene, μ
is the overall mean, g denotes the effect of genotype, t the
effect of LPS treatment, gt the effect of the interaction
between genotype and treatment, and e the residual error
variance. Individual entered the analysis as a random
effect.
Data inspection showed that the distribution of vari-
ances approximately follows the expectation (assuming
all genes have equal variances), i.e. a scaled χ2-distribu-
tion with four degrees of freedom. Since averaging over
all genes gives a much better estimate of residual varia-
tion than single gene estimates of error variance, we esti-
mated the effect sizes for each of the three effects
y genotype treatment genotype treatment egti g t gt gti= + + + × +m ( ) ,
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(genotype, treatment, and genotype × treatment) as stan-
dardized coefficients for each gene, i.e., by dividing the
effects by the average of the square root of the residual
variance over all genes. This approach is similar to the
use of fold changes instead of t-values (see [37,38], but
see [39] for a critique). To test the robustness of our
method we also used moderated t-statistics [40]. Since
the outcomes of both types of analysis were qualitatively
and quantitatively similar (data not shown), we only
report the former analysis.
Of the 7546 genes analyzed, 7546 × 0.05 ≈ 377 genes are
expected to be significantly different by chance alone,
about half of them up and half of them down (assuming a
type I error rate or statistical significance level of α =
0.05). To address this multiple testing problem, we used a
false discovery rate (FDR) of 0.05 to detect genes that are
likely to be differentially regulated between genotypes,
influenced by LPS treatment, or both. Results based on
genes lists assuming α = 0.01 did not change the qualita-
tive outcome of our analyses (data not shown).
To refine our single gene analysis in terms of biological
function we performed gene ontology (GO) analysis,
using the classification developed by the GO Consortium
http://www.geneontology.org/. This classification con-
sists of three structured controlled vocabularies (or
ontologies) that describe gene products in terms of their
associated "biological processes", "cellular components",
or "molecular functions", in a species-independent man-
ner. We restricted our analysis to the "biological process"
annotation, as this category is easiest to interpret and
since we observed substantial overlap between this group
of genes and the "molecular function" category. For GO
analysis within the "biological process" category, genes
were ordered into GO classes. We separately contrasted
each class with all other classes by performing t-tests
(assuming normality of the data) and nonparametric Kol-
mogorov-Smirnov tests (relaxing the assumption of nor-
mality) on standardized coefficients. Since data were
approximately normally distributed, results differed little
between the tests; we therefore only report t-tests.
Analysis of putative regulatory elements
To relate the gene expression effects of genotype and LPS
treatment to putative regulatory regions, we used bioin-
formatic analysis to identify putative cis-regulatory ele-
ments in the 5'UR, i.e. TFBSs in the promoter region, and
3'UTR regulatory elements (including miRNA targets).
We aimed to use the same alignment methods and similar
methods for defining these different cis-regulatory
regions.
Sequence information was obtained from the Univer-
sity of California Santa Cruz (UCSC) Genome Bioinfor-
matics site http://genome.ucsc.edu; in particular, the
mouse mm7-assembly and the human hg18-assembly
data were used. For each gene, we extracted the region up
to 8 kb upstream from the transcription start point
(5'UR) and the 3'UTR, using the UCSC KnownGenes
database, which has a higher coverage than the RefSeq
database. For the few protein coding genes with multiple
entries, we randomly kept a single entry. If an adjacent
gene was closer than 8 kb in the UR, the recorded
upstream sequence was truncated before the start of the
transcribed region of the adjacent gene. We also per-
formed our analyses with shorter regions and obtained
similar results (data not shown).
Homologous human and mouse genes were acquired
using the HomoloGene database http://
www.ncbi.nlm.nih.gov/homologene (48.1) at the National
Center for Biotechnology Information (NCBI). Only
genes with reciprocal best BLAST hit e-values were
selected. For each gene, we aligned the 5'UR and the
3'UTR separately using LAGAN [41]. To obtain a reason-
able alignment of the 5'UR, we truncated the longer
sequence so that it had the same distance from the pre-
sumed transcription start site as that of the shorter
sequence, despite the fact that in one or the other species
the 5'UR might be shortened by another gene. This trun-
cation thus only affected the most upstream part of the
region. For orthologous 3'UTRs, we allowed for different
lengths because of the generally higher similarity and
thus easier alignment. We validated this method exten-
sively (results not shown, see B. Fuhrmann, unpublished
diploma thesis) [42]. In particular, we found that pairwise
alignments with LAGAN performed better than available
multi-species alignments, because fewer regions were
excluded and because placement of insertions and dele-
tions in multi-species alignments is problematic.
To identify putative regulatory elements (TFBSs and
3'UTR regulatory sequences) we used a comparative
genomics approach. Xie et al. [14] inferred conserved
motifs in the 5'UR (putative TFBSs) and 3'UTR (contain-
ing many miRNA cognate sequences) using a comparison
among mammalian genomes. While we are aware that
regulatory sequences may lie outside of these regions
(e.g., in the 5' untranslated region (5'UTR) or in introns,
especially the first), we refrained from including such
regions, for two reasons. First, as a transcribed region, the
5'UTR imposes more (and different) constraints on regu-
latory sequences than the untranscribed 5'UR that are
difficult to account for. Second, the search space would
have increased vastly with the inclusion of introns, which
also would have caused alignment problems. We note
that the list of Xie et al. [14] contains several unknown
putative TFBSs, whereas some known TFBSs are not
included. Furthermore, Xie et al. [14] do not distinguish
between TFBSs of some related transcription factors (e.g.,
ISGF3 and most other IRF TFBSs). We used these puta-
tive regulatory sequences as raw data for our analysis. We
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parsed each gene of the aligned human and mouse
sequences for conserved motifs in the lists given in Xie et
al. [14]: for putative TFBSs see Supplementary Material
Table S3, for putative 3'UTR regulatory sequences Sup-
plementary Material Table S4, and for conserved octamer
motifs in the 3'UTR Supplementary Material Table S5,
respectively. To exclude false positives, a motif was
defined as conserved if it occurred in the homologous
mouse and human sequence at the same position of the
alignment in any of its forms (including the reverse com-
plement for the 5'UR). To validate the ability of this com-
parative genomics approach to identify 5'UR TFBSs we
used publicly available microarray data http://symat-
las.gnf.org/SymAtlas/ on samples from diverse mouse tis-
sues (see Additional File 9). We noticed some
discrepancies between the annotation of Xie et al. [14]
and the list of miRNAs in miRBase http://www.mir-
base.org/[15-17]. Conserved octameric sequences in [14]
were therefore re-annotated using the list in miRBase
release 10.1. An association was called if the distal
octamer of the mature miRNA matched perfectly to the
octameric region.
To analyze TFBSs and 3'UTR regulatory elements, we
contrasted the normalized effect coefficients of genes
that had at least one conserved regulatory element with
those of the rest of the genes. As for the GO analysis, we
performed both t-tests Kolmogorov-Smirnov tests. Since
the outcome of these tests was again qualitatively similar,
we only report t-tests.
For our TFBS analysis (see above) we used a rather
stringent definition [14], filtered out all non-conserved
and non-alignable motifs, and excluded all weakly
expressed genes, such that our analysis was based on only
40 genes containing an IRF/ISRE TFBS, with many
known IFN-inducible genes missing. To extend this anal-
ysis and to explore different inclusion criteria for 5'UR
TFBSs, we produced a list of 187 known IFN-responsive
genes from the literature (without differentiating between
type I IFN and IFNγ-responsive genes) and asked how
many of these genes show expression changes in our
experiment. As above, we analyzed the standardized
effects of genotype, treatment, and genotype × treatment
on gene expression (Additional File 3, Table 1). Further-
more, we compared IFN-responsive genes to all other
genes with respect to IRF/ISRE or GAS TFBSs in their
5'UR. We used different criteria for including or exclud-
ing TFBSs, i.e. we report enrichments for conserved and
nonconserved TFBSs that differ in the length of the
upstream search region (Additional File 3, Table 2). We
also lowered the specificity of our screening for TFBSs of
known IFN-induced transcription factors by allowing for
mismatches (data not shown).
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FINAL DISCUSSION 
 
Tyk2 is a non-receptor tyrosine kinase that is involved in the Jak-Stat signalling pathway. 
The essential contribution of Tyk2 to various cytokine and growth factor signalling 
pathways has been reported [27] and, accordingly, Tyk2 has a broad spectrum of effects 
on host immunity, which range from protective to detrimental. During most microbial 
infections, Tyk2 acts beneficial for the host, mainly due to its contribution to IFN!/" and 
IL-12 signalling [32-34, 43-46, 101]. Conversely, deletion of Tyk2 confers resistance to 
LPS-induced endotoxin shock [25, 47]. Endotoxin shock is accompanied by the release of 
massive amounts of cytokines and proinflammatory mediators (e.g. TNF!, IL-6, IL-1", 
IFN!/", IFN# and nitric oxide [NO]). Whereas the early systemic production of IL-6, IL-1", 
TNF! and NO is unimpaired in Tyk2 knock-out mice, they fail to induce IFN# after LPS 
challenge [25, 47]. Mice deficient for Tyk2 or IFN" are similarly resistant to LPS-induced 
shock, demonstrating the crucial role of IFN!/" [25]. However, since Tyk2 is only partially 
required for IFN!/" signalling, additional Ifnar-independent pathways might contribute to 
the high resistance of Tyk2 knockout mice.  
In order to examine the global influence of Tyk2 on transcription we performed expression 
profiling in response to LPS. Transcriptional analysis in thioglycollate-elicited peritoneal 
macrophages (PM) revealed that Tyk2 most prominently impacts on baseline expression 
of many IFN-stimulated genes (ISGs), whereas in response to LPS most of those genes 
were upregulated similar to wildtype cells. These data extend previous observations on 
the expression of specific ISGs [25] to a global scale and establish the importance of Tyk2 
for constitutive, low-level IFN!/" signalling. Interestingly, we found that Tyk2 is critical for 
the downregulation of metabolic genes upon LPS treatment, in particular genes involved 
in lipid metabolism [102]. Consistently, Tyk2 modulates the expression of several 
metabolic proteins in bone marrow-derived macrophages ([103] and Grunert T., Strobl B. 
et al, manuscript in preparation). It is known for some time that immunity, inflammation, 
and lipid metabolism are interconnected [104]. Since the molecular mechanisms behind 
are not well understood, it will be interesting to further analyse the contribution of Tyk2 to 
these complex regulatory networks. 
Transcription of many Tyk2-regulated genes has been observed to be even more 
compromised by the absence of Ifnar1 (unpublished data). Nevertheless, we can show 
that IL-17 and IL-17F are two genes, which are regulated by Tyk2 at the transcriptional 
level, largely independent of type I IFN signalling. During the last years IL-17 and IL-17F 
have gained prominence due to their involvement in several inflammatory and 
autoimmune diseases [85]. Besides Th17 cells, a growing number of cell types have been 
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reported to be critically involved in IL-17 secretion depending on the stimulus [83]. 
Although we can show that IL-17 is produced by peritoneal macrophage cultures following 
LPS treatment in vitro, we found no evidence for IL-17 producing macrophages in spleens 
after intraperitoneal LPS administration in vivo. We identified #$ T cells and pDCs as the 
cell types responsible for Tyk2-dependent IL-17 production in spleens. However, whether 
both cell types are similarly required and serve non-redundant functions has to be 
clarified. Furthermore, it is not yet clear if cell-intrinsic or -extrinsic signalling/responses 
require Tyk2. Lck- or CD11c-Cre recombinase-driven celltype-specific knockout of Tyk2 in 
T cells or DCs, respectively and adoptive transfer of Tyk2-deficient hematopoietic cells in 
wildtype mice or vice versa would be valuable tools to address these questions in future 
studies.  
In contrast to its detrimental functions in autoimmunity, IL-17 has a vital role in protecting 
the host from infection. Important key functions of IL-17 are the induction of neutrophil 
recruitment and the increase of their microbicidal activity. Consistently, loss of IL-17R 
signalling during non-severe polymicrobial sepsis induced by cecal ligation and puncture 
(CLP) leads to increased mortality due to defective neutrophil recruitment and activity 
[105]. On the other hand, decreased neutrophil recruitment after blocking IL-17 or deleting 
the IL-17 receptor turned out to be beneficial for the host following lethal TNF challenge 
[100]. Blocking neutrophil recruitment to affected organs has mainly beneficial effects in 
TNF- and LPS-induced shock as it protects the host from excessive tissue damage [106-
108]. We hypothesise therefore that Tyk2 contributes to LPS-induced shock by regulating 
IL-17 mediated neutrophil recruitment and tissue destruction. IL-17 also induces the 
expression of inducible NO synthase (iNOS, NOS2) and NO production in various cell 
types. NO has been shown to mediate the microbicidal activity of neutrophils, and organ-
specific defects in iNOS induction in Tyk2-deficient mice following LPS challenge in vivo 
have been reported previously [109]. Similar to IL-17 (data not shown), iNOS expression 
in livers was induced by a Tyk2-dependent, but Ifnar1-independent mechanism. 
Nevertheless, whether IL-17 indeed induces iNOS expression in this context has to be 
clarified. 
Using a proteomics approach, we identified several proteins that are differentially 
regulated in wildtype and Tyk2-deficient bone marrow-derived macrophages (BMDM) 
after LPS treatment. Further analyses revealed unperturbed mRNA expression in the 
absence of Tyk2 for some of these proteins, indicating the involvement of Tyk2 in 
posttranscriptional regulation. We show that Tyk2 specifically suppresses IL-1" 
expression in BMDM at the translational level, thereby unravelling a novel pathway of IL-
1" regulation. Even though the precise mechanism remains unknown, we provide 
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evidence for the involvement of IFN!/" signalling. In line with our in vitro data we report 
increased levels of IL-1" in the peritoneal lavages of Tyk2-deficient mice following 
intraperitoneal LPS administration. However, serum IL-" levels were decreased and also 
intranasal application of LPS led to slightly but significantly reduced IL-1" levels in the 
lung of Tyk2-/- mice (data not shown). Taken together, our data clearly show that Tyk2 is 
intricately linked to the regulation of IL-1". Since IL-1" is regulated at multiple levels, other 
pathways may counter-regulate Tyk2-mediated translational regulation. Whether IL-1" is 
augmented or suppressed by Tyk2 likely depends on several factors including the 
stimulus, the duration of treatment and the cell type(s) involved. Furthermore, local and 
systemic levels of IL-1" may be regulated differently. Delineating the possible protective 
functions of Tyk2 in IL-1" driven diseases (e.g. turpentine-induced local inflammation, 
contact hypersensitivity and collagen induced arthritis) will be an attractive target for future 
studies. Notably, Tyk2-deficient mice are more sensitive to contact hypersensitivity [110], 
and the underlying mechanisms are still unclear. 
One recurrent issue that came up during our studies concerns the heterogeneity of 
different types of macrophages. It has been described that macrophages can differ in their 
cytokine profiles and transcription factor activities dependent on the isolation and/or 
differentiation procedure [111]. In our studies we show IL-17 expression in PM, while we 
could not detect IL-17 in BMDM. Conversely, Tyk2-mediated suppression of IL-1" protein 
could exclusively be monitored in BMDM but not PM. It is comprehensible that these two 
types of macrophages, which can be regarded as resident and inflammatory, respectively, 
respond differentially to a given stimulus. Nevertheless, it remains an important 
unresolved issue in macrophage biology to which degree those two types correlate to 
distinct macrophage populations in vivo. 
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Myeloid STAT3 plays an inhibitory rather than a stimulatory role for
the induction of IL-17 and IL-17F mRNA expression by LPS
Fig. 4. Macrophages derived from Stat3fl/fl or STAT3Lyzs-/- mice (i.e. mice harbouring a myeloid specific STAT3
deletion) were treated with 100 ng/ml LPS for the times indicated or left untreated. The expression of (A) IL-17,
(B) IL-17F an
Type I interferon-independent requirement of Tyk2
for LPS-mediated IL-17 expression in murine macrophages
R. Stiefvater1, B. Strobl1, E. Hofmann1,
T. Kolbe2, U. Reichart1, C. Lassnig1,2, C. Vogl1, V. Poli3, M. Müller1,2
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2University Center Biomodels Austria, University of Veterinary Medicine, Vienna, Austria,
3Department of Genetics, Biology and Biochemistry,
Molecular Biotechnology Center, University of Turin, Turin, Italy.
INTRODUCTION
IL-17, which is the signature cytokine of the T helper cell lineage Th17, is
known to play an essential role in host defense and autoimmunity (1).
Amongst the IL-17 family, IL-17F has similar biological functions to IL-17.
Although several cell types have been reported to produce IL-17, underlying
mechanisms are still poorly characterized. Tyrosine kinase 2 (Tyk2), a
member of the Janus kinase family, is involved in signal transduction of a
number of different cytokines, most prominently type I interferons (IFNα/β) (2,
3). We have reported previously that Tyk2-deficient macrophages have
selective defects in their response to lipopolysaccharide (LPS) and virus
infection (2, 4). We report here Tyk2-specific defects in the IL-17 production
in thioglycollate elicited peritoneal macrophages in response to LPS.
SUMMARY
Here we show, that LPS induces IL-17 expression in peritoneal macro-
phages in a Tyk2-dependent manner. IL-17 and IL-17F mRNA and protein
expression are upregulated upon LPS treatment and are strongly reduced in
the absence of Tyk2. Induction is only slightly reduced in IFNAR1-deficient
macrophages, demonstrating that Tyk2 does not exert the positive regulatory
function through its involvement in IFNα/β signalling. We furthermore show,
that, in contrast to the development/maintenance of Th17 cells, STAT3 is not
required but rather inhibitory for LPS induced IL-17 expression in peritoneal
macrophages.
CD11b+ cells produce IL-17 in response to LPS
in peritoneal macrophage cultures
Fig. 6. Wildtype macrophages
were treated for 24 h with
100 ng/ml LPS or left untreated.
Brefeldin A was added to the
cultures for the last 12 h. Cells
were harvested and stained for
CD11b and intracellular IL-17.
Cells were analysed by flow
cytrometry. Numbers in the
upper right quadrants indicate
the percentage of CD11b+IL-17+
cells in peritoneal macrophage
cultures.
LPS-mediated STAT3 activation is impaired in the absence of Tyk2
mm
Fig. 3. Macrophages of the genotypes indicated, were
treated with 100 ng/ml LPS or left untreated. At the
times indicated, total cell lysates were prepared and
subjected to Western blot analysis. Membranes were
probed with Abs specific for (A) phosphorylated
STAT1 (pSTAT1) or STAT1 protein (STAT1) and (B)
phosphorylated STAT3 (pSTAT3) or STAT3 protein
(STAT3). Protein loading was controlled by reprobing
with anti-pan-ERK Ab (panERK).
A
B
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Tyk2 is required for IL-17 protein production in response to LPS
Fig. 2. Macrophages of the
genotypes indicated, were
treated with 100 ng/ml LPS for
the times indicated or left un-
treated (untr.). IL-17 accu-
mulation was measured in cell
culture supernatants by ELISA.
Data are depicted as mean
± SE (A) from 2 independent
experiments and (B) from
10 independent experiments
(* p=0.04, ** p<0.001).
A B
Fig. 5. Macrophages derived
from STAT3fl/fl or STAT3Lyzs-/-
mice (i.e. mice harbouring a
myeloid specific STAT3 dele-
tion) were treated with LPS
(100 ng/ml) for the times
indicated or left untreated
(untr.). IL-17 accumulation was
measured in cell culture super-
natants by ELISA. Data are
depicted as mean ± SE (A)
from 2 independent experi-
ments and (B) from 3 indepen-
dent experiments (comprising
cells from 4 to 6 individual mice;
* p=0.012).
A B
(C) At the times indicated, total cell lysates were
prepared and subjected to Western blot analysis.
Membranes were probed with Abs specific for
phosphorylated STAT1 (pSTAT1), STAT1 protein
(STAT1) or STAT3 protein (STAT3). Protein loading
was controlled by reprobing with anti-pan-ERK Ab
(panERK).
C
LPS-induced IL-17 protein production is increased
in the absence of STAT3
IL-17F
IL-17
(B) IL-17F and (C) TNFα mRNA was analysed by
qRT-PCR. UBE2D2 was used for normalisation and
expression levels were calculated relative to un-
treated STAT3fl/fl cells (STAT3fl/fl 0h). Data are
depicted as mean ± SE from at least 3 independent
experiments per time point; expression levels in (A)
and (B) were significantly different between the
genotypes at all time points (p≤0.05 for 8 h post treat-
ment, all other time points p≤0.01); expression levels
in (C) were only significantly different at 0 h (p≤0.05).
B
A
C TNFα
IL-17 and IL-17F mRNA expression is induced by LPS in a
Tyk2-dependent and IFNα/β-receptor (IFNAR1)-independent manner
Fig.1. Macrophages of the genotypes indicated, were
treated with 100 ng/ml LPS for the times indicated or
left untreated. The expression of (A) IL-17, (B) IL-17F
and (C) TNFα mRNA was analysed by qRT-PCR.
UBE2D2 was used for normalisation, and expression
levels were calculated relative to untreated wildtype
cells (WT 0h). Data are depicted as mean ± SE
derived from at least 3 independent experiments per
time point; except for untreated cells (0 h), mRNA
expression levels in (A) and (B) were significantly
different between Tyk2-/- and both other genotypes at
all time points (p≤0.01), mRN A expression levels in
IFNAR1-/- differ from those in
IL-17 IL-17F
A
 th s  in WT cells from 0 h up to 6 h post treatment (p≤0.05) and no significant difference is
obtained at later time points. (C) mRNA expression was not significantly different between the genotypes, except at
24 h post treatment between WT and both other genotypes (p≤0.05).
C
TNFα
B
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SUMMARY 
Here we show that IL-17 induction is considerably reduced in the absence of 
Tyk2 but largely independent of functional IFN!/" signaling upon LPS treatment 
in thioglycolate-elicited peritoneal macrophages. Interestingly, signal transducer 
and  activator  of  transcription  3  (Stat3)  is  not  required  for  LPS-induced  IL-17 
production. In contrast to its essential role in the differentiation and maintenance 
of  Th17  cells,  Stat3  exerts  inhibitory  rather  than  stimulatory  effects  on  LPS-
induced IL-17 production in macrophages.  Similarly,  Tyk2 is indispensable for 
IL-17 production in spleens following LPS challenge in vivo, whereas absence of 
the  interferon  !/"  receptor  1  (Ifnar1)  did  not  affect  splenic  IL-17  levels.  We 
furthermore show that  #$  T cells,  and to a lesser extent,  pDCs are the main 
sources of IL-17 in spleens following intraperitoneal administration of LPS. 
IL-17 production in macrophages is induced by LPS in a Tyk2-
dependent  and  largely  IFN!/"-receptor  (Ifnar1)-independent 
manner 
Fig.  1.  WT, Tyk2-/-  and Ifnar1-/-  macrophages were treated with 100 ng/ml  LPS for  the times indicated or  left 
untreated. The expression of (A) IL-17 mRNA was analyzed by qRT-PCR. Ube2d2 was used for normalization, and 
expression levels were calculated relative to untreated wildtype cells (WT 0 h). Data are depicted as mean ± SE 
derived from at least 3 independent experiments per time point; except for untreated cells (0 h, mRNA expression 
levels  were significantly  different  between Tyk2-/-  and both other  genotypes at  all  time points  (p!0.01),  mRNA 
expression levels in Ifnar1-/- differed from those in WT cells from 0 h up to 6 h post treatment (p!0.05). (B) IL-17 
accumulation was measured in cell  culture supernatants with ELISA. Data are depicted as mean ± SE from 4 
independent experiments (comprising cells from 10 individual mice; * p<0.05, ** p<0.001). 
Stat3 has an inhibitory function in the induction of IL-17 by LPS 
mm 
Fig. 5. WT mice were injected i.p. with LPS (1mg per 20g body weight) or left untreated. Subsequently, mice were 
injected i.v. with 0.25 mg Brefeldin A and after 6 h challenge CD19-depleted spleen cells were analyzed by FACS. Dot 
plots show intracellular staining for IL-17 in (A) pDCs and (B) #$  T cells. Aggregates and dead cells were excluded 
based on FSC-H versus FSC-A plots. Among the resulting live cell singlets, pDCs were gated for CD3–Siglec-H+ and 
#$ T cells for CD3+#$TCR+. Numbers in the gates indicate the percentage of IL-17+ cells in total (A) CD3–Siglec-H+ 
cells  or  (B)  CD3+#$TCR+  cells.  Right  panels  show IL-17+  cells  as mean ± SD from 3 independent  experiments;           
(** p!0.001).  
Fig. 4. (A) WT or (B) WT and Tyk2-/- mice were injected i.p. with LPS (1mg per 20g body weight) or left untreated. 
Following 6 h LPS challenge spleen cells were separated by successive magnetic cell sorting. (A, B) IL-17 mRNA 
expression in different spleen cell populations was analyzed by qRT-PCR. Expression levels were calculated relative 
to the endogenous control (Ube2d2). Data are depicted as mean ± SE from 2 independent experiments. 
Fig. 3. (A) WT, Tyk2-/- and Ifnar1-/- or (B) WT and Rag2-/- mice were injected i.p. with LPS (1mg per 20g body weight) 
or left untreated. At the times indicated IL-17 mRNA expression in spleens was analyzed by qRT-PCR. Ube2d2 was 
used for normalization and expression levels were calculated relative to the untreated WT (WT 0 h). (A) Data are 
depicted as mean ± SD from at least 4 mice in 3 independent experiments per time point; no significant difference 
was observed between mRNA expression levels in Ifnar1-/- and those in WT spleens at any time point tested. (B) 
Data are depicted as mean ± SD from at least 5 mice in 3 independent experiments per time point; expression levels 
were only significantly different between untreated (0 h) Rag2-/- and WT mice; * p!0.01, ** p!0.001. 
Fig. 2. WT (Stat3fl/fl) and Stat3-deficient (Stat3Lyzs-/-) macrophages were treated with 100 ng/ml LPS for the times 
indicated  or  left  untreated.  Expression  of  (A)  IL-17  mRNA was  analyzed  by  qRT-PCR.  Ube2d2  was  used  for 
normalization and expression levels were calculated relative to untreated Stat3fl/fl  cells  (Stat3fl/fl  0  h).  Data are 
depicted as mean ± SE from at least 3 independent experiments per time point; expression levels were significantly 
different between the genotypes at all time points (p!0.05). (B) IL-17 accumulation was measured in cell culture 
supernatants by ELISA. Data are depicted as mean ± SE from 3 independent experiments (comprising cells from 6 
individual mice; * p=0.012). 
Splenic IL-17 mRNA expression is dependent on Tyk2 but not 
on  the  presence  of  mature  T-  and  B-cells  following  LPS 
challenge in vivo 
CD11b+  cells  do  not  substantially  contribute  to  IL-17  mRNA 
expression in spleens after LPS challenge in vivo 
#$ T cells and pDCs are the major sources of IL-17 in spleens 
B 
INTRODUCTION 
During the last years it became evident that in addition to Th17 cells interleukin 
17 (IL-17) is also produced by innate immune cells (1). However, mechanisms of 
IL-17 induction in non-Th17 cells and the contribution of different innate immune 
cell types to IL-17 production in vivo are still largely elusive. The Janus kinase 
family member tyrosine kinase 2 (Tyk2) is mainly involved in IFN!/" and IL-12 
signaling  (2,  3).  We  have  reported  previously  that  macrophages  from  Tyk2-
deficient mice exhibit selective defects in response to lipopolysaccharide (LPS) 
and virus infection (2, 4). We show here, that Tyk2 is required for LPS induced 
IL-17 production both in primary macrophages in vitro and in spleens in vivo.  
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